

May 2018

The Effect of Kinesiology Tape During Isotonic Knee Flexion Extension Exercise on Time to Fatigue, Rate, and Quadricep Muscle Oxygenation

Yu-Wei Wang

University of Wisconsin-Milwaukee

Follow this and additional works at: <https://dc.uwm.edu/etd>



Part of the [Industrial Engineering Commons](#)

Recommended Citation

Wang, Yu-Wei, "The Effect of Kinesiology Tape During Isotonic Knee Flexion Extension Exercise on Time to Fatigue, Rate, and Quadricep Muscle Oxygenation" (2018). *Theses and Dissertations*. 1946.
<https://dc.uwm.edu/etd/1946>

This Thesis is brought to you for free and open access by UWM Digital Commons. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of UWM Digital Commons. For more information, please contact open-access@uwm.edu.

THE EFFECT OF KINESIOLOGY TAPE DURING ISOTONIC KNEE FLEXION
EXTENSION EXERCISE ON TIME TO FATIGUE, RATE, AND QUADRICEP
MUSCLE OXYGENATION

by

Yu-Wei Wang

A Thesis Submitted in
Partial Fulfillment of the
Requirements for the Degree of

Master of Science
in Engineering

at

The University of Wisconsin-Milwaukee

May 2018

ABSTRACT

THE EFFECT OF KINESIOLOGY TAPE DURING ISOTONIC KNEE FLEXION EXTENSION EXERCISE ON TIME TO FATIGUE, RATE, AND QUADRICEP MUSCLE OXYGENATION

by

Yu-Wei Wang

The University of Wisconsin-Milwaukee, 2018
Under the Supervision of Professor Naira Campbell-Kyureghyan

Some Kinesiology Tape manufacturers claim that Kinesiology Tape (KT) can enhance performance and increase blood flow. Therefore, this study recruited 14 healthy male subjects (college population, 182.9 ± 5.1 cm, 76.52 ± 10.2 kg). to complete an eight-day KT intervention experiment. On Day 1 and Day 2 the subjects did not wear KT. During Days 3 to 6 the subjects wore the KT on their dominant leg (treatment leg) only. Limb dominance was defined by asking the subjects which leg they use to kick a ball. During Days 7 and 8 the subjects did not wear KT. Furthermore, the KT was not worn on the non-dominant leg (control leg) during the study. During testing each subject performed a fatiguing isotonic flexion/extension exercise with a single leg on a Biodex, and switched to the other leg after the first leg exercise was complete. Fatigue was defined by when a subject could no longer perform the exercise.

The time to fatigue (TTF), number of cycles, and rate (number of cycles over TTF) were recorded as performance measures. Muscle oxygenation data including sitting baseline, minimum rSO_2 levels, and time to minimum rSO_2 levels in the trial were assessed to determine the influences of KT on blood flow. The confidence level

in this research was set at 95%. The time series was analyzed to check the root cause of any performance enhancement.

The results suggest that KT did not enhance the performance since the TTF and rate increased most of the days in both the taped and control legs. Furthermore, the time series analyses support the finding that the TTF and rate performance was enhanced by a learning effect. The muscle oxygenation results suggest the Vastus Medialis (VM) minimum rSO_2 were increased by the KT. Even though the Vastus Lateralis (VL) sitting baseline show a statistically significant increase ($p=0.045$), the Power analysis suggest that the results need more subjects to avoid type I error. In conclusion, the KT type and brand utilized in this research did not support the manufacturers claim regarding enhanced performance. However, the muscle oxygenation results did show a difference when KT was on the treatment leg.

© Copyright by Yu-Wei Wang, 2018
All Rights Reserved

TABLE OF CONTENTS

| | |
|---|-----|
| LIST OF FIGURES | vii |
| LIST OF TABLES | xii |
| ACKNOWLEDGMENTS | xv |
| Chapter 1: Introduction | 1 |
| 1.1 Background | 1 |
| 1.2 Previous Research | 2 |
| 1.3 Research Gaps and Study Motivation | 7 |
| 1.4 Specific Aims and Hypotheses | 9 |
| Chapter 2: Methods | 16 |
| 2.1 Subjects | 16 |
| 2.2 Experiment Design | 16 |
| 2.3 Equipment and Data Collection | 20 |
| 2.5 Analysis | 25 |
| Chapter 3 Results | 28 |
| 3.1 Fatiguing of Isotonic Knee Flexion Extension Exercise | 28 |
| 3.2 Muscle Oxygenation | 41 |
| Chapter 4 Discussion | 70 |
| 4.1 Fatiguing of Isotonic Knee Flexion Extension Exercise | 70 |
| 4.2 Muscle Oxygenation | 75 |
| 4.3 Summary | 81 |
| 4.4 Study Limitations | 82 |

| | |
|--|-----|
| Chapter 5 Conclusion..... | 84 |
| References..... | 85 |
| APPENDICES | 93 |
| Appendix A: Isotonic Flexion/Extension Exercise TTF..... | 93 |
| Appendix B: Isotonic Flexion/Extension Exercise Rate..... | 96 |
| Appendix C: Sitting Baseline in VM/VL Muscles rSO ₂ Levels Before the Test | 99 |
| Appendix D: Minimum rSO ₂ Levels in VM/VL Muscle During the Task..... | 103 |
| Appendix E: Time to Minimum rSO ₂ Levels During the Trial | 106 |
| Appendix F: rSO ₂ Levels in VM/VL Muscle During the Isotonic Flexion/Extension Exercise..... | 109 |

LIST OF FIGURES

| | |
|--|----|
| Figure 1: Kinesio-Tape (KT) | 17 |
| Figure 2: The isotonic flexion/extension experiment input and output variables..... | 19 |
| Figure 3: Subject’s initial position on Biodex | 20 |
| Figure 4: Odds ratio scales..... | 21 |
| Figure 5: Relative risk scales | 22 |
| Figure 6: The NIRS system | 24 |
| Figure 7: NIRS sensor placement | 25 |
| Figure 8: Odds ratio for association between treatment and control leg and changes in TTF based on acute KT application..... | 29 |
| Figure 9: The acute effect of KT application on TTF in the treatment leg. ♦ indicates an outlier. * indicates statistical significance between median TTF (indicated by horizontal line within bar) for D2 and D3..... | 29 |
| Figure 10: Relative risk for legs and changes in TTF based on the duration of KT application | 31 |
| Figure 11: Box plot of TTF throughout the duration of KT application in treatment leg. ♦ indicates an outlier. * indicates statistical significance between median TTF (indicated by horizontal line within bar) for D3 to D4, D5, D6 | 31 |
| Figure 12: Box plot showing the TTF on D2, D6, and D7 for both the control and treatment leg. ♦ indicates an outlier. * indicates statistical significance between median TTF (indicated by horizontal line within bar) for D7 compare to D6 and D2 in treatment leg and control leg | 33 |
| Figure 13: Odds ratio for association between treatment and control leg and changes in rate based on acute KT application..... | 35 |
| Figure 14: Box plot of the rate on D2 and D3 for both the treatment and control legs. ♦ indicates | |

an outlier. * indicates statistical significance between median Rate (indicated by horizontal line within bar) for D2 and D3.....36

Figure 15: Relative risk for legs and changes in rate based on the duration of KT application37

Figure 16: Box plot of rate for D3, D4, D5, and D6. ♦ indicates an outlier. * indicates statistical significance between median Rate (indicated by horizontal line within bar) for D3 to D4, D5, D6.....38

Figure 17 : Box plot of rate for D2, D6, and D7 for both the treatment and control leg. ♦ indicates an outlier. * indicates statistical significance between median rate (indicated by horizontal line within bar) for D7 compare to D6 and D2 in treatment leg and control leg ...40

Figure 18: Odds ratio for association between the treatment and control leg VM muscles and changes in muscle oxygenation sitting baseline based on acute KT application.....42

Figure 19: Box plot of VM sitting baseline rSO₂ levels for D2 and D3 in the treatment leg. ♦ indicates an outlier. * indicates statistical significance between mean sitting baseline (indicated by horizontal line within bar) for D2 and D343

Figure 20: Relative risk for legs and changes in muscle oxygenation sitting baseline based on the duration of KT application.....44

Figure 21: Box plot of VM muscle oxygenation sitting baseline for D3, D4, D5, D6. ♦ indicates an outlier. * indicates statistical significance between mean muscle oxygenation sitting baseline (indicated by horizontal line within bar) for D3 to D4, D5, D645

Figure 22: Box plot of VM sitting baseline muscle oxygenation for the treatment legs on D2, D6, and D7. ♦ indicates an outlier. * indicates statistical significance between mean VM muscle oxygenation sitting baseline (indicated by horizontal line within bar) for D7 compare to D6 and D2 in treatment leg VM muscles46

Figure 23: Odds ratio for association between treatment and control leg and changes in VL

| | |
|--|----|
| muscle oxygenation sitting baseline based on acute KT | 47 |
| Figure 24: Box plot of VL muscle oxygenation sitting baseline for D2 and D3 in the treatment leg. ♦ indicates an outlier. * indicates statistical significance between mean sitting baseline (indicated by horizontal line within bar) for D2 and D3 | 48 |
| Figure 25: Relative risk for legs and changes in TTF based on the duration of KT application | 49 |
| Figure 26: Box plot of VL muscle oxygenation sitting baseline for D3, D4, D5, D6. ♦ indicates an outlier. * indicates statistical significance between mean muscle oxygenation sitting baseline (indicated by horizontal line within bar) for D3 to D4, D5, D6 | 50 |
| Figure 27: Box plot of treatment leg VM muscle oxygenation sitting baseline for D2, D6, and D7. ♦ indicates an outlier. * indicates statistical significance between mean VM muscle oxygenation sitting baseline (indicated by horizontal line within bar) for D7 compare to D6 and D2 in treatment leg VM muscles | 51 |
| Figure 28: Box plot of VM muscles of minimum rSO ₂ levels on D2 and D3 for both the treatment and control leg. ♦ indicates an outlier. * indicates statistical significance between mean minimum rSO ₂ levels (indicated by horizontal line within bar) for D2 and D3. | 52 |
| Figure 29: Box plot of VM minimum rSO ₂ levels in the treatment leg for D3, D4, D5, and D6. ♦ indicates an outlier. * indicates statistical significance between mean minimum rSO ₂ levels (indicated by horizontal line within bar) for D3 to D4, D5, D6 | 54 |
| Figure 30: Box plot of the treatment leg VM minimum rSO ₂ levels on D2, D6, D7. ♦ indicates an outlier. * indicates statistical significance between mean VM minimum rSO ₂ levels (indicated by horizontal line within bar) for D7 compare to D6 and D2 in treatment leg VM muscles..... | 55 |
| Figure 31: Box plot of the treatment leg VL minimum rSO ₂ levels for D2 and D3. ♦ indicates an outlier. * indicates statistical significance between mean minimum rSO ₂ levels (indicated | |

by horizontal line within bar) for D2 and D356

Figure 32: Box plot of VL minimum rSO₂ levels in the treatment leg for D3, D4, D5, and D6.
 ♦ indicates an outlier. * indicates statistical significance between mean minimum rSO₂ levels (indicated by horizontal line within bar) for D3 to D4, D5, D657

Figure 33: Box plot of treatment leg VL minimum rSO₂ levels for D2, D6, and D7. ♦ indicates an outlier. * indicates statistical significance between mean VL minimum rSO₂ levels (indicated by horizontal line within bar) for D7 compare to D6 and D2 in treatment leg VL muscles.....59

Figure 34: Example of muscle oxygenation trial (Subject 5, treatment leg, on D3) 60

Figure 35: Box plot of treatment leg VM time to minimum rSO₂ levels for D2 and D3. ♦ indicates an outlier. * indicates statistical significance between mean time to minimum rSO₂ levels (indicated by horizontal line within bar) for D2 and D3 61

Figure 36: Box plot of VM time to minimum rSO₂ for D3, D4, D5, and D6. ♦ indicates an outlier. * indicates statistical significance between mean VM time to minimum rSO₂ levels (indicated by horizontal line within bar) for D3 to D4, D5, D6 63

Figure 37: Box plot of the treatment leg VM time to minimum rSO₂ levels for D2, D6, and D7. ♦ indicates an outlier. * indicates statistical significance between mean VM time to minimum rSO₂ levels (indicated by horizontal line within bar) for D7 compare to D6 and D2 in treatment leg VM muscles 64

Figure 38: Box plot of the treatment leg VL time to minimum rSO₂ levels for D2 and D3. ♦ indicates an outlier. * indicates statistical significance between mean time to minimum rSO₂ levels (indicated by horizontal line within bar) for D2 and D3 65

Figure 39: Box plot of VL time to minimum rSO₂ levels for D3, D4, D5, and D6 in treatment leg. ♦ indicates an outlier. * indicates statistical significance between mean time to minimum rSO₂ levels (indicated by horizontal line within bar) for D3 to D4, D5, D6 67

Figure 40: Box plot of the treatment leg VL time to minimum rSO₂ levels for D2, D6, and D7♦ indicates an outlier. * indicates statistical significance between mean VL time to minimum rSO₂ levels (indicated by horizontal line within bar) for D7 compare to D6 and D2 in treatment leg VL muscles68

Figure 41: rSO₂ levels - D4 Subject 9 control Leg - an example of when VL and VM have similar rSO₂ consumption and trends. The time displayed in the graph is the respective end of that trial.....81

Figure 42: rSO₂ levels - D4 Subject 12 treatment Leg - An example of when VM and VL rSO₂ levels decrease until the end of the trial. The time displayed in the graph is the respective end of that trial.....81

LIST OF TABLES

| | |
|--|----|
| Table 1: Summary of the reviewed articles | 13 |
| Table 2: Experimental design schedule overview | 18 |
| Table 3: TTF performance odds ratio table | 21 |
| Table 4: TTF performance relative risk table | 22 |
| Table 5: Number of subjects in each TTF response category based on acute KT application | 28 |
| Table 6: Number of subjects in each TTF response category for each 24 hour period of KT application through D6 (72 hours after KT application) | 30 |
| Table 7: Number of subjects in the category of TTF changes based on the residual of KT application results. D7 (the day after 24 hours KT removed) compare to D6 (The last day of test with KT application), D2 (A day before KT application wearing)..... | 32 |
| Table 8: The results of Wilcoxon analysis in D2 (no KT effect) compare to D3 through D8 (the day with KT and after KT removed) to answer the residual effect of TTF is caused by KT or other factor..... | 34 |
| Table 9: Number of subjects in each category of rate response based on acute KT application | 35 |
| Table 10: Number of subjects in each category of rate response for each 24 hour period of KT application through D6 (72 hours after KT application) | 37 |
| Table 11: Number of subjects in each change in rate category based on the residual of KT application results. D7 (the day after 24 hours KT removed) compare to D6 (The last day of test with KT application), D2 (A day before KT application wearing)..... | 39 |
| Table 12: The results of Wilcoxon analysis in D2 (no KT effect) compare to D3 through D8 (the day with KT and after KT removed) to answer the residual effect is caused by KT or other factor | 41 |
| Table 13: Number of subjects in each category in VM muscle oxygenation sitting baseline | |

| | |
|--|----|
| based on acute KT application..... | 42 |
| Table 14: Number of subjects in each category of VM muscle sitting baseline response for each 24 hours period of KT application through D6 (72 hours after KT application) | 44 |
| Table 15: Number of subjects in each category of VM muscle oxygenation sitting baseline changes based on the residual of KT application results. D7 (the day after 24 hours KT removed) compare to D6 (The last day of test with KT application), D2 (A day before KT application wearing) | 45 |
| Table 16: Number of subjects in each category of VL muscle oxygenation sitting baseline changes based on acute KT application..... | 47 |
| Table 17: Number of subjects in each category of VL muscle oxygenation sitting baseline changes for each 24 hours period of KT application through D6 (72 hours after KT application) | 49 |
| Table 18: Number of subjects in each category of VL muscle oxygenation sitting baseline changes based on the residual of KT application results. D7 (the day after 24 hours KT removed) compare to D6 (The last day of test with KT application), D2 (A day before KT application wearing) | 51 |
| Table 19: Number of subjects in each category of VM minimum rSO ₂ levels changes based on acute KT application..... | 52 |
| Table 20: Number of subjects in each category of VM minimum rSO ₂ changes for each 24 hours period of KT application through D6 (72 hours after KT application)..... | 53 |
| Table 21: Number of subjects' in each category of VM minimum rSO ₂ changes based on the residual of KT application results. D7 (the day after 24 hours KT removed) compare to D6 (The last day of test with KT application), D2 (A day before KT application wearing)..... | 55 |
| Table 22: Number of subjects in each category of changes in VM minimum rSO ₂ levels based on acute KT application..... | 56 |

Table 23: Number of subjects in each category of changes in VL minimum rSO₂ levels for each 24 hours period of KT application through D6 (72 hours after KT application)57

Table 24: Number of subjects in each category of changes in VL minimum rSO₂ levels based on the residual of KT application results. D7 (the day after 24 hours KT removed) compare to D6 (The last day of test with KT application), D2 (A day before KT application wearing)...58

Table 25: Number of subjects in each category of changes in VM time to minimum rSO₂ based on acute KT application.....61

Table 26: Number of subjects in each category of changes in VM time to minimum rSO₂ levels for each 24 hours period of KT application through D6 (72 hours after KT application).....62

Table 27: Number of subjects in each category of changes in VM time to minimum rSO₂ levels based on the residual of KT application results. D7 (the day after 24 hours KT removed) compare to D6 (The last day of test with KT application), D2 (A day before KT application wearing)64

Table 28: Number of subjects in each category of changes in VM time to minimum rSO₂ levels based on acute KT application.....65

Table 29: Number of subjects in each category of changes in VL time to minimum rSO₂ levels for each 24 hours period of KT application through D6 (72 hours after KT application).....66

Table 30: Number of subjects' in each category of changes in VL time to minimum rSO₂ levels based on the residual of KT application results. D7 (the day after 24 hours KT removed) compare to D6 (The last day of test with KT application), D2 (A day before KT application wearing)68

Table 31: Subjects grouped by learning effect, placebo effect, and rate control effect.....75

ACKNOWLEDGMENTS

First of all, I would like to acknowledge my advisor, Dr. Naira Campbell-Kyureghyan, for providing me this opportunity to obtain a Master's of Science in Engineering degree and to teach me not only the hard skill like English, research methods, and so on, but also the soft skills like communication, and teamwork. Secondly, I would like to thank my two committee members, Dr. Wilkistar Otieno and Dr. Stephen Cobb, for the assistance they provided me a lot of statistics and precious comments that helped me reorganize my thinking. I would also like to acknowledge all the subjects in this study. A special thanks is extended to Joe Pliner, Madiha Ahmed, Stephanie Bolin, and Blake Johnson for their assistance in data collection and all the help in my thesis.

Chapter 1: Introduction

1.1 Background

Muscle soreness and muscle pain are common side effects after exercising and strenuous work activity. Usually people take pills or use ointments to reduce the pain, which might have some side effect or require dietary restrictions, etc. As an alternative, in the 1970s, Dr. Kenzo Kase developed Kinesiology Tape (KT) which advertises that it can help rehabilitate individuals suffering from muscle pain and soreness. Not only do KT manufacturer's claim to balance the muscles strength during exercise, but also delay fatigue, improve endurance and oxygenation of the muscle, and reduce pain and the likelihood of injury.

In previous studies the KT has been applied to the leg or arm muscles (Gart, 2016), which are the body parts that usually get sore after exercising. Different sports, people and injuries will have different demands. However, KT can also be used on other muscles such as the waist (Gak, 2011). The research also states that KT may be a supplementary treatment method for acute LBP, and could be used in the prevention and treatment of occupational LBP. Another study looked at the neck muscles (González-Iglesias, 2009) which claims that KT significantly improves the pain and cervical range of motion, but may not be clinically meaningful.

In 1980 Dr. Kase established the Kase Chiropractic Institute and the kinesiо-taping method that provided correct application guidance to the user. Correct application of the KT is supposed to enhance the efficiency of recovery (Kase, 2003). Dr. Kase, who invented the tape, explained that the fundamental concept of KT is that, after adhesion, it will stretch the skin to promote blood flow and improve

performance, which will function to both protect from injury and enhance rehabilitation following injury.

During the 1990s, after the KT patent expired, many competitor companies started introducing similar tapes. The tape manufacturer's nowadays claim that the tape can not only improve recovery from muscle pain, but also can enhance user's performance, reduce fatigue, improve blood flow to the muscles, and even prevent injury. Numerous athletes have begun using the tape to enhance performance as well. For example, a famous basketball player in the NBA - James Harden - puts on the tape for every game. James Harden's reasoning is that he believes that KT can prevent him from getting injured, and can also maximize his performance through increasing blood flow.

1.2 Previous Research

A Google Scholar search revealed over 20,000 research articles related to KT were published since 1990. Due to the nature of KT claims, most of the research studies were targeting a specific muscle or a group of muscles to which the tape was applied. Further, different parameters of muscle performance (isometric, isokinetic, isotonic) were commonly used in the investigations

Isometric: An exercise where the subject exerts against a fixed object (velocity equals zero), with the position determined by the experiment designer, and exertions must be maintained for at least six seconds. Isometric exercises are used to determine the maximum muscle strength (Perrine, 1969).

Isokinetic: Eccentric/concentric contraction at a constant velocity defined by the experiment designer. The resistance varies throughout the range of motion and the test is used to determine maximum strength (Perrine, 1969).

Isotonic: A dynamic motion flexion/extension exercise with constant resistance and variable velocity. The maximum strength occurs over a short portion of the range of motion determined by the properties of the limb lever system (Iellamo, 1997).

The acute effect of KT application has been widely researched at a number of joints, including the ankle (Simon, 2014; Fayton, 2013; Bicipi, 2012; Shields, 2013; Briem, 2011; Wilson, 2015; Halseth, 2004), neck (González-Iglesias, 2009; Saavedra-Hernandez, 2012), legs (Wong, 2012; Fu, 2008; Huang, 2011; Słupik, 2007), back (Gak, 2011), and shoulder (Kaya, 2010; Simsek, 2013; Hsu, 2009). However, only a few published studies have investigated longer-term KT application effects (H.J. Tsai, 2009; A. Ibrahim, 2015; A. Castro-Sánchez, 2012; D. Duracoglu, 2005; S. Bicipi, 2012; M. Gramatikova, 2016; M. Thelen, 2008).

Some previous studies have also been conducted with patients to investigate recovery efficiency (Ptak, 2013; Kaya, 2010; Luque-Suarez, 2014; Ibrahim; MacGregor, 2005; Castro-Sánchez, 2012; Duracoglu, 2005; Briem, 2011; Shields, 2013; Jackson, 2016; Simon, 2014; González-Iglesias, 2009). Other studies have been conducted using healthy participants to investigate the effect on performance (Konishi, 2013; Poon, 2015; van Dieen, 2007; Gak, 2011; Tsai, 2009; Huang, 2011; Soylu, 2011; Słupik, 2007; Aktas, 2011; Lee, 2010).

A summary of some of the studies conducted using KT or otherwise having direct relevance to the current study is contained in Table 1. The studies included in this review were chosen based on the claims from Kinesiology Tape to enhance exercise performance and increase muscle oxygenation. Finally, other studies are included that investigated similar topics to the current study: leg exercises, case

control studies, the use of healthy subjects, or duration effects.

A study by Ruggiero et al. (2016) considered a 30 minute KT application to the lumbar spine of 24 low-back pain patients during isometric flexion-extension exercise. While the findings from this study indicate that after the KT was in place for a period of time that there was an enhancement of seated balance compared to a control, whether the results were caused by KT or by a learning effect is unknown because the experimental design did not consider daily data collection. In addition, the findings indicate that KT did not enhance the seated balance control in the short-term since the improvement persisted after the KT was removed, suggesting that the root cause is related to learning effect.

KT has also been studied in the area of low back pain (LBP) since it is a very prevalent worldwide problem and affects 60% to 85% of the population during their lifetime (Burton, 1996). A three-day KT study found that the subjects who have LBP had improved muscle function and a progressive increase in trunk performance after KT application in addition to physical therapy (Gak, 2011).

A recent study investigated KT application for neck pain relief and posture correction. In the neck pain relief study (González-Iglesias, 2009), forty-one patients were chosen, and separated randomly into 2 groups. The experimental group had KT application with tension on the subjects' cervical spine; the placebo group had the same KT application, but it was placed without tension. The cervical range-of-motion was collected immediately after placement of the KT and 24 hours after taping. The results showed that the KT was more effective than the placebo.

In a postural correction study (Luque-Suarez, 2014) 130 participants were included and the two groups of KT application (with and without tension) were split

randomly. At 1 minute, 10 minutes, 60 minutes and 24 hours after taping the FPI score was collected to check on postural changes. The results demonstrated that 24 hours of KT application was not found to be effective for patients with a pathological foot pronation.

Kaya (2010) conducted a study comparing KT application in addition to physical therapy modalities for patients with shoulder impingement syndrome. Significantly better arm and shoulder disability scores were achieved with the KT when compared to therapy alone. The authors also suggest that the KT could be used to cure shoulder impingement syndrome.

KT has also been used to aid in the recovery of proprioception among knee osteoarthritis patients. Sensorimotor training was compared to KT application and the training produced a better outcome (Ibrahim, 2015). The authors conclude that traditional sensorimotor training cannot be replaced by KT application therapy.

A study involving healthy subjects investigated the effect of KT placement on the lumbar portion of the spine and found significant improvements in subject maximal extension peak torque (Knapman, 2016). A competitor of KT claimed that it not only reduces patellofemoral pain (PFP), but also enhanced subjects' isometric strength performance (MacGregor 2005).

Some previous studies collected data from healthy subjects to assess hand (Fu, 2008) and knee joint (Pliner, 2015) performance during isokinetic exercises after KT application. Both studies revealed that a short-term taping didn't exhibit any significant improvements. The findings from another study by Wong (2012) showed no effect on isokinetic test knee torque generation with KT application using a Biodex. However, the time to peak extension torque in that study was significantly

reduced with KT application. The authors did not believe that KT application enhanced performance. However, the authors do not explain whether the finding was due to a “learning” effect or just a “placebo”.

In another study (Poon, 2014), 30 healthy subjects participated using 3 different treatments: true facilitative KT, sham KT, and no KT. A knee isokinetic task was designed to investigate if the KT application on the quadriceps affects the normalized peak torque, normalized total torque, and time to peak torque at different speeds. The KT application was reported to either have a positive effect on the subjects or a “placebo” effect was present.

The possible benefits of KT were also tested for the rectus abdominis muscle during force-velocity parameters of trunk flexors using Biodex equipment (Plak, 2013). A study group (32 people with tape) and a control group (20 people with no tape) were recruited, and each subject performed an isokinetic task with 5 consecutive trunk flexion/extensions at a fixed angular velocity. The study group had KT applied after the first test. No significant difference was found between groups in this short-term isokinetic test.

Ibrahim et al. (2015) designed an 8 week long test to determine the influence of KT and sensorimotor training on the efficiency of osteoarthritis (OA) patients during knee isokinetic exercises, but the study did not record and test consistently over the entire period. The result show that even though both techniques showed significant enhancement in performance, the sensorimotor training provided better improvement in exercise performance, which was collected by Biodex and a visual analogue scale, but the KT application produced greater pain reduction. However, it is possible that patients had recovered by themselves after 8 weeks.

J.H. van Dieen (2009) used a Biodex, EMG, and NIRS to assess when the trunk extensor muscles fatigue during low-level activity, and how muscle activity and muscle oxygenation change in healthy subjects. The results show that NIRS and EMG are not correlated with each other. Although KT application is absent in this research, it nevertheless provides a good reference for discussing fatigue along with muscle oxygenation.

Maximal de-oxygenation of the muscles was examined in a study by Moalla (2006) without KT. 12 healthy children participated, and an isokinetic dynamometer recorded data during subject isometric exercise performance. NIRS and EMG were also used to record the muscle oxygenation and muscle activity. The results suggest that decrease in muscle oxygenation and blood volume is related to isometric exercise.

1.3 Research Gaps and Study Motivation

Based on a review of the published KT research several gaps in knowledge can be identified. Although many KT research studies were designed to test with an exercise task, only a few of the studies were tested with isotonic exercise (Bicici, 2012; Lee, 2011; Pliner, 2015; Cheng, 2005). Bicici (2012) used isotonic exercise on ankle sprains, and Lee (2011) tested the ankle but without KT, Cheng (2005) assessed leg muscle recovery of isotonic power, and the study from Pliner (2015) is the pilot for this research. Most of the published articles (Knapman 2016; Wong 2012; Poon 2014; Vithouk, 2010; Ptak 2013; Fu, 2012; Aktas, 2011; Lins, 2012) used isometric or isokinetic (Moalla, 2006; MacGregor, 2005; Kaya, 2010; Gramatikova, 2016; Briem, 2011; Fahs, 2015; Castro-Sánchez, 2012; Ruggiero, 2015) exercise to examine muscle strength and torque produced. In this study,

isotonic exercise will be used to assess the performance of knee muscle fatiguing and fill the gap in knowledge.

Experiment duration is another gap. Although several studies used a long duration test (Table 1), very few have recorded the data every day. Some studies have only conducted testing at the beginning and end of the experiment (Tsai, 2009; Ibrahim, 2015), while others have only recorded the data after a period of time (Castro-Sánchez, 2012; Duracoglu, 2005; Bicici, 2012; Gramatikova, 2016; Thelen, 2008; Akbas, 2011). While a small number of papers collect the data throughout the experiment duration (Paoloni, 2011; Saavedra-Hernandez, 2012; Tsai, 2010; Simsek, 2013), none of the studies investigated fatigue or muscle oxygenation.

In particular, only two pilot studies discuss the muscle oxygenation in KT application (Pliner, 2015; Shah, 2017), which is an important topic to investigate due to the manufacturer claims that the muscle oxygenation will be changed by KT, and the increasing of muscle oxygenation can reduce the risk of injury. Regional oxygen saturation (rSO_2) level is the variable that this study measured to present the muscle oxygenation result. In addition, only the pilot study in this research (Pliner, 2015) discusses the duration of flexion/extension exercise and its relationship with time to fatigue (TTF) and rate (frequency).

In this study, an eight-day isotonic knee flexion/extension fatigue experiment in which the data was collected every day was designed. The performance data collected were muscle regional oxygen saturation (rSO_2) levels, time to fatigue (TTF), number of cycles and rate (calculated by number of cycles over TTF). None of the variables have been adequately explored in the past with regards to KT application. The chosen task was knee flexion-extension since the study was a

case-control study design, and the dominant and non-dominant legs have been shown to have similar performance for the task (van der Harst, 2007). Other research also states that the two legs have close performance on different tasks (K. McCurdy, 2005; I. Sannicandro, 2014).

1.4 Specific Aims and Hypotheses

Based on the research gaps identified above, the goals of this case-control research study are threefold:

- i. Assess the effectiveness of KT during an isotonic fatiguing knee flexion/extension exercise protocol by measuring the TTF and the number of cycles or rate.
- ii. Investigate the effect of KT application over an extended number of days.
- iii. Examine the residual effect after removal of the KT application.

The specific aims are:

1. Quantify the effect of acute KT application on TTF of the knee joint during a fatiguing isotonic knee flexion/extension exercise, investigate the effect of the duration of KT application on the TTF, and also examine the residual effect on TTF after KT is removed.

Hypothesis 1: The acute KT application will delay the TTF in the treatment leg during the fatiguing isotonic knee flexion/extension exercise, the effect will become more prominent as the duration of tape application increases, and additionally have a residual effect to maintain or increase the TTF after KT is removed.

Hypothesis 1a: The acute KT application will delay the TTF in the

treatment leg.

Hypothesis 1b: The duration of KT application will have a positive effect on the TTF.

Hypothesis 1c: The residual effect will maintain the delay of TTF after removal of KT.

2. Quantify the effect of acute KT application on the rate of knee joint motion during a fatiguing isotonic knee flexion/extension exercise, investigate the effect of the duration of KT application on the rate, and also examine the residual effect on rate after KT is removed.

Hypothesis 2: The acute KT application will increase the rate in the treatment leg during the fatiguing isotonic knee flexion/extension exercise, the effect will be more prominent with duration of tape application, and the improvements will be maintained or increased after removal of the KT.

Hypothesis 2a: The acute KT application will increase the rate in the treatment leg.

Hypothesis 2b: The rate will increase with continued KT application.

Hypothesis 2c: The residual effect after KT application will exist and increase the rate in the treatment leg.

3. Quantify the sitting baseline of rSO₂ level increase due to acute KT application to the knee joint before the fatiguing isotonic knee flexion/extension exercise, investigate the effects of duration of KT application on sitting baseline rSO₂ level changes, and additionally examine the residual effect on the sitting baseline rSO₂ levels after KT removal.

Hypothesis 3: The acute KT application will increase the sitting baseline of muscle rSO₂ levels in the treatment leg before the fatiguing isotonic knee flexion/extension exercise, the effect will be more prominent with duration of tape application, and additionally will also have a residual effect to maintain or increase the sitting baseline of muscle rSO₂ levels after KT removal.

Hypothesis 3a: The sitting baseline of rSO₂ levels will increase after acute KT application.

Hypothesis 3b: The sitting baseline of rSO₂ levels will increase with duration of KT application.

Hypothesis 3c: The sitting baseline of rSO₂ levels will increase by the residual effect from KT application.

4. Quantify the minimum of rSO₂ level changes due to acute KT application to the knee joint during the fatiguing isotonic knee flexion/extension exercise, investigate the effects of duration of KT application on minimum rSO₂ level changes, and additionally examine the residual effect on the minimum rSO₂ levels after KT removal.

Hypothesis 4: Acute KT application will change the minimum of muscle rSO₂ levels in the treatment leg flexors/extensors during the fatiguing isotonic knee flexion/extension exercise, the effect will be more prominent with duration of tape application, and additionally there will be a residual effect to maintain or change the minimum rSO₂ levels after KT removal.

Hypothesis 4a: The minimum of rSO₂ levels will change after acute KT application.

Hypothesis 4b: The minimum of rSO₂ levels will change due to duration of KT application.

Hypothesis 4c: The residual effect after KT application will exist and change the minimum rSO₂ levels in the treatment leg.

5. Quantify the time to minimum rSO₂ level changes due to acute KT application to the knee joint during the fatiguing isotonic knee flexion/extension exercise, investigate the effects of duration of KT application on time to minimum rSO₂ level changes, and additionally examine the residual effect after KT removal on the time to minimum rSO₂ levels.

Hypothesis 5: The acute KT application will change the time to minimum of muscle rSO₂ levels in the trial in the treatment leg flexors/extensors during the fatiguing isotonic knee flexion/extension exercise, the effect will be more prominent with duration of tape application, and additionally there will be a residual effect to maintain or change the time to minimum rSO₂ levels after KT removal.

Hypothesis 5a: The time to minimum of rSO₂ levels in the trial will change after acute KT application.

Hypothesis 5b: The time to minimum of rSO₂ levels in the trial will change due to duration of KT application.

Hypothesis 5c: The residual effect after KT application will exist and change the time to minimum of rSO₂ levels in the treatment leg.

Table 1: Summary of the reviewed articles

| Article Information | | | | Article Topics | | | | | | | |
|---------------------|-----------------|------|---|----------------|---------------------|----------------|--------------|----------|----------|-------------|--------------------|
| | Authors | Date | Journal | KT Tape | Healthy Participant | Test with Legs | Case-control | Isotonic | Duration | Dynamometer | Muscle Oxygenation |
| 1 | Oscar M.H. Wong | 2012 | Physical Therapy in Sport | V | V | V | | | | V | |
| 2 | T.C Fu | 2008 | Journal of Science and Medicine in Sport | | V | V | | | | | |
| 3 | H.Y. Chang | 2010 | Physical Therapy in Sport | V | V | | | | | | |
| 4 | Y. Konishi | 2013 | Journal of Science and Medicine in Sport | V | V | V | | | | V | |
| 5 | K.Y. Poon | 2015 | Manual Therapy | V | V | V | | | | V | |
| 6 | Y. Shah | 2017 | Journal of Bodywork and Movement Therapies | V | V | | | | | | V |
| 7 | H. Preece | 2016 | Journal of Bodywork & Movement Therapies | V | V | | | | | | |
| 8 | W. Moalla | 2006 | Journal of Sports Sciences | | V | V | | | | V | V |
| 9 | J. H. van Dieen | 2007 | Journal of Electromyography and Kinesiology | | V | | | | | V | V |
| 10 | J. Pliner | 2015 | Conference Paper | V | V | V | V | V | | V | V |
| 11 | A. Ptak | 2013 | Journal of Back and Musculoskeletal Rehabilitation | V | | | | | | V | |
| 12 | H.B. Gak | 2011 | International Journal of Occupational Medicine and Environmental Health | V | V | | V | | | | |
| 13 | E. Kaya | 2010 | Clinical Rheumatology | V | | | V | | | | |
| 14 | A. Luque-Suarez | 2014 | Physiotherapy | V | | | | | | | |
| 15 | M. Gart | 2016 | Hand Clinics | V | V | | V | | | | |
| 16 | H.J. Tsai | 2009 | Support Care Cancer | V | V | | V | | V | | |
| 17 | C.Y. Huang | 2011 | BioMedical Engineering OnLine | V | V | V | V | | | | |
| 18 | A. Ibrahim | 2015 | International Journal of Therapies and Rehabilitation Research | V | | V | V | | V | V | |
| 19 | A.K. Burton | 1996 | Spine | | | | | | | | |

| | | | | | | | | | | | | |
|----|----------------------|------|--|---|---|---|---|---|---|---|---|---|
| 20 | K. Kase | 2003 | Clinical Therapeutic Applications of The KinesioTaping Method | V | | V | | | | | | |
| 21 | K. MacGregor | 2005 | Journal of Orthopaedic Research | V | | V | | | | | | |
| 22 | H.J. Knapman | 2016 | Physical Therapy in Sport | V | V | | V | | | | V | |
| 23 | M.H. Lee | 2011 | Journal of Physical Therapy Science | V | V | | | | | | | |
| 24 | A.R. Soyulu | 2011 | Med Sport. | V | V | | | | | | | |
| 25 | I. Vithoulk | 2010 | Isokinetics and Exercise Science | V | V | | | | | | | |
| 26 | A. Słupik | 2007 | Orto Traum Rehab. | V | V | | | | | | | |
| 27 | A. Yoshida | 2007 | Res Sport Med. | V | V | | | | | | | |
| 28 | G. Aktas | 2011 | Isokinetics and Exercise Science | V | V | | V | | | | | |
| 29 | J.H. Lee | 2010 | Journal of Physical Therapy Science | V | V | | | | | | | |
| 30 | J. González-Iglesias | 2009 | Journal of Orthopaedic & Sports Physical Therapy | V | | | V | | | | | |
| 31 | J.T. Han | 2014 | Journal of Physical Therapy Science | V | V | | | | | | | |
| 32 | A.M. Castro-Sánchez | 2012 | Journal of Physiotherapy | V | | | V | | V | | | |
| 33 | C.A. Fahs | 2014 | Clinical Physiology and Nuclear Medicine | | V | V | | | | | V | V |
| 34 | M. Nakajima | 2013 | The International Journal of Sports Physical Therapy | V | V | | | | | | | |
| 35 | S. Semple | 2012 | Journal of Physical Therapy Science | V | V | | | | | | V | |
| 36 | D. Duracoglu | 2005 | Journal of Clinical Rheumatology | | | | V | V | | V | V | |
| 37 | S. Bicici | 2012 | The International Journal of Sports Physical Therapy | V | | | | | V | V | | |
| 38 | M. Gramatikova | 2016 | Sport Science | V | | | V | V | | V | | |
| 39 | S. Zhang | 2016 | Journal of Science and Medicine in Sport | V | V | | V | | | | V | |
| 40 | K. Briem | 2011 | Journal of Orthopaedic & Sports Physical Therapy | V | | | | | | | | |
| 41 | C.A. Shields | 2013 | American Orthopaedic Foot & Ankle Society | V | | | | | | | | |
| 42 | K.Y. Lee | 2011 | International Journal of Precision Engineering and Manufacturing | | V | | | | V | | | |
| 43 | D. DeLorey | 2004 | The Physiological Society | | V | V | | | | | | V |
| 44 | J. Simon | 2014 | Clinical Journal of Sport Medicine | V | | | V | | | | V | |
| 45 | S. Fayson | 2013 | Research in Sports Medicine | V | V | | | | | | | |
| 46 | K. Jackson | 2016 | Journal of Athletic Training | V | | | | | | | | |

| | | | | | | | | | | | |
|----|-----------------------|------|--|---|---|---|---|---|---|---|--|
| 47 | S. Ruggiero | 2017 | Journal of Sports Sciences | V | V | | | | | | |
| 48 | M. Thelen | 2008 | Journal of Orthopaedic & Sports Physical Therapy | V | | | V | | V | | |
| 49 | T. Halseth | 2004 | Journal of Sports Science and Medicine | V | V | | | | | | |
| 50 | C.A.A. Lins | 2013 | Manual Therapy | V | V | | V | | | V | |
| 51 | G. Strutzenberger | 2015 | Europe Journal of Sports Science | V | V | | | | V | | |
| 52 | E. Akbas | 2011 | Acta Orthopaedica et Traumatologica Turcica | V | | | | | V | | |
| 53 | A. Cheng | 2005 | Journal of Applied Physiology | | V | V | | V | | V | |
| 54 | S. Álvarez-Álvarez | 2014 | Journal of Back and Musculoskeletal Rehabilitation | V | V | | | | | | |
| 55 | G. Llopis | 2012 | Fisioterapia | V | | | | | V | | |
| 56 | M. Paoloni | 2011 | Europe Journal of Physiology Rehabilitation | V | | | | | V | | |
| 57 | A. Aystar | 2011 | Isokinetics and Exercise Science | V | | | | | | V | |
| 58 | M. Saavedra-Hernandez | 2012 | Journal of Orthopaedic & Sports Physical Therapy | V | | | | | V | | |
| 59 | C.T. Tsai | 2010 | Journal of Musculoskeletal Pain | V | | | V | | V | | |
| 60 | H.H Simsek | 2013 | Acta Orthopaedica et Traumatologica Turcica | V | | | | | V | V | |
| 61 | Y.H. Hsu | 2009 | Journal of Electromyography and Kinesiology | V | | | | | | | |

Chapter 2: Methods

The University of Wisconsin-Milwaukee Institutional Review Board approved all the study materials and protocols in this research. (Protocol #15.372). All experimental sessions were conducted at the University of Wisconsin-Milwaukee Spine Biomechanics Laboratory (USRB 289).

2.1 Subjects

Fourteen healthy male college students volunteered to participate in this project and signed a consent form prior to testing. The subjects ranged in height and weight which averaged 182.9 ± 5.1 cm and 76.52 ± 10.2 kg respectively. Subjects were asked whether they had a leg injury in the past six months, or if they had ever sustained any other serious injury. Individuals who had a recent leg injury or an injury that would prevent them from performing the knee flexion/extension protocol optimally were excluded from the test.

The study protocol was explained to the subjects upon arrival and they were asked to conduct their normal daily activities during the entire testing duration (8 days). The dominance was determined by asking the subjects which leg they use to kick a ball.

2.2 Experiment Design

An eight-day case-control study was designed to examine the effect of KT on a knee joint isotonic flexion/extension fatigue protocol. Commercially available “Kinesio-Tape” brand KT was used in this study (Figure 1). All data was collected bilaterally (left and right knee) following the same protocol over eight consecutive days. The overview of the experimental design is presented in Table 2.



Figure 1: Kinesio-Tape (KT)

retrieved from: <https://www.kttape.com/kt-tape-pro-kinesiology-tape>

During the experiment no KT was applied to the subject's non-dominant leg (control leg). The dominant leg (treatment leg) was left untaped (nKT) for the first two days. The KT was applied on Day 3 and was kept on through Day 6. The KT was then removed. The final two testing sessions were conducted 24 hours after KT removal (Days 7 & 8). Testing with no KT application on Day 1 was used as a “training” session and was not used for analysis. The data from Day 2 to Day 8 was used to establish individual performance differences with and without KT, as well as for the assessment of potential “learning” effect (K. Jackson et al., 2016; J.T. Han et al., 2014; C. Fahs et al., 2015). The test began at the same time every day (± 2 hours), in order to eliminate any potential influence of time of day on performance. The start time was determined by the start of testing on the first day (H. Chtourou et al., 2012).

Table 2: Experimental design schedule overview

| | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 |
|---------------|-------|-------|-------|-------|-------|-------|-------|-------|
| Treatment leg | nKT | | KT | | | | nKT | |
| Control Leg | nKT | | | | | | | |

On Day 3 of the protocol, KT was applied to the dominant knee per the manufacturer’s protocol (Kase, 2003). KT placement, and subsequent sensor placement, was conducted by the same researcher each day for all subjects to avoid any error due to differing techniques of multiple researchers. The following outcome parameters of interest were considered and are described in more detail in the subsequent sections:

Rate = number of cycles (flexion/extension) per second

Time to fatigue (TTF) = time to the point that the subject could no longer perform the task

rSO₂ = percent of muscle oxygenation




Figure 2: The isotonic flexion/extension experiment input and output variables

2.3 Equipment and Data Collection

2.3.1 Biodex

The knee flexion/extension exercise was recorded using a Biodex dynamometer System 4 (Biodex Medical Systems, NY).



Figure 3: Subject's initial position on Biodex

Subjects were strapped down on the positioning chair with two seatbelts. One belt was positioned across the chest, and another belt was tied on the tested leg as depicted in Figure 3. The isotonic test was administered for knee flexion and extension exercises with the resistant load set at 40 pounds and no velocity control. The initial position of the knee was set at 90-degree flexion angle.

The data was recorded at 100 Hz and included joint position, velocity, number of cycles and duration of the task. Time to fatigue (TTF) and the rate (calculated by number of cycles over TTF) were the main biomarkers of interest during each testing

session.

The TTF was used to calculate the odds ratio (OR) to describe the association between acute KT application and time to fatigue. Table 3 and Equation 1 explain the calculation of the odds ratio, including the parameters required for each leg. The odds ratio result was determined by the scale presented in Figure 4.

Table 3: TTF performance odds ratio table

| TTF | Treatment leg | Control Leg |
|-------------------|---------------|-------------|
| TTF Increased | a | b |
| TTF Not Increased | c | d |

$$Odds\ ratio = \frac{a/c}{b/d} \quad Eq\ 1$$

a = number of subjects with increased TTF on the treatment leg

b = number of subjects with increased TTF on the control leg

c = number of subjects with no increase in TTF on the treatment leg

d = number of subjects with no increase in TTF on the control leg




Figure 4: Odds ratio scales

The relative risk (RR) considered the time factors. Therefore, relative risk was calculated to examine the effect of duration of KT application (after 24 hours, 48

hours, and 72 hours of wearing). Table 4 and Equation 2 explain the calculation of the relative risk, including the parameters required for each leg. The relative risk result was determined by the scale presented in Figure 5.

Table 4: TTF performance relative risk table

| TTF | TTF Increased | TTF Not Increased |
|---------------|---------------|-------------------|
| Treatment leg | a | b |
| Control Leg | c | d |

$$Relative\ risk = \frac{a/(a+b)}{c/(c+d)} \quad Eq\ 2$$

a = number of subjects with increased TTF on the treatment leg

b = number of subjects with no increase TTF on the treatment leg

c = number of subjects with increase in TTF on the control leg

d = number of subjects with no increase in TTF on the control leg




Figure 5: Relative risk scales

The rate of knee flexion/extension was calculated by dividing the total number of cycles by time to fatigue or total task time (Eq 3). All three parameters are related, and to determine the true meaning of any changes all three must be considered. For example, TTF may increase, but if no change occurred in the number of cycles, it

means that the velocity decreased and therefore the change may not be biomechanically significant.

$$Rate = \frac{Number\ of\ Cycles}{Time\ to\ Fatigue} \quad Eq\ 3$$

As with TTF, odds ratio and relative risk were used to discuss the acute KT application and the duration of KT wearing.

The percent change of TTF and rate was calculated to normalize the data and unify the scale. The percent change is necessary when discussing the comparison between legs (Eq 4), since the percent change explains the TTF or rate data increase or decrease more directly (Eq 5, Eq 4).

$$Percent\ Change\ in\ TTF = \frac{TTF\ Day_i}{TTF\ Day_2} \quad i = 3, 4, 5, 6, 7, 8 \quad Eq\ 4$$

$$Percent\ Change\ in\ Rate = \frac{Rate\ Day_i}{Rate\ Day_2} \quad i = 3, 4, 5, 6, 7, 8 \quad Eq\ 5$$

2.3.2 Near-infrared spectroscopy (NIRS): The EQUANOX 7600 (Nonin Medical Inc., MN) two channel Near Infrared System (NIRS) was used to measure the regional muscle oxygen saturation (rSO₂) and is shown in Figure 6. Two sensors were placed on the Vastus Lateralis (VL) and Vastus Medialis (VM) muscles, which are the two largest muscles of the quadriceps muscle group as depicted in Figure 7. Before placing the electrodes, the sensor placement area was cleaned with alcohol, and after placement the sensors were secured with a bandage to prevent movement.

NIRS data was recorded at a rate of 0.25 Hz and was represented as percent of rSO₂ at any given time. The rSO₂ recordings during the fatiguing isotonic knee flexion/extension exercise testing session were taken continuously from the

beginning to the end. The NIRS data normalization was done as follows:

$$\text{Normalized } rSO_2 = \frac{rSO_2 \text{ levels on Day } i}{rSO_2 \text{ levels at the beginning of trial on Day } i}$$

$$i = 1,2,3,4,5,6,7,8 \quad \text{Eq 6}$$

After normalizing the data, the trends and the minimum rSO_2 level were extracted for each trial. Instead of using the time when the minimum drop occurred to determine time to fatigue, the percentage of the TTF previously described was calculated for further analysis (Eq 7).

$$\text{Percentage of TTF to minimum } rSO_2 \text{ levels} = \frac{\text{Time to minimum } rSO_2 \text{ Day}_i}{\text{TTF Day}_i}$$

$$i = 1,2,3,4,5,6,7,8 \quad \text{Eq 7}$$



Figure 6: The NIRS system




Figure 7: NIRS sensor placement

2.3.3 Video recording:

All the experiments were recorded using a standard digital video camera (Sony, Japan) in order to visually assess the subjects' performance. Some subjects did not perform full cycles at the end of their trial and the video recording combined with Biodex leg positioning data were used to determine the exact TTF and number of cycles.

2.5 Analysis

2.5.1 Statistical Analysis

One of the methods that could assess the outcome performance in this research is the trend from Day 2 to Day 8 in TTF and rate response. The slope in

time series could explain the trend rising or descending; the equation below is the time series (Eq 8). The time series can forecast future performance, and check the data point trends already collected (C. Chatfield, 2016; D. Montgomery, 2015). Time series analysis is commonly used in economic and biology studies. The coefficient β is the slope of the trend, and the β comparison calculated by paired t-test indicates how the exercise performance changes. Time series is used to investigate whether Hypothesis 1 and 2 are rejected or failed to reject.

$$Y_t = y_0 + \beta * t \quad t = \text{Day } 1, 2, 3, \dots, \infty \quad \text{Eq 8}$$

β = The slope (coefficient) of the time series

y_0 = Initial point of response

Y_t = The forecasted response on Day t

The outliers were identified using Eqs 9-11.

$$IQR = Q_3 - Q_1 \quad \text{Eq 9}$$

$$\text{Low Outlier Point} = Q_1 - (1.5 \times IQR) \quad \text{Eq 10}$$

$$\text{High Outlier Point} = Q_3 + (1.5 \times IQR) \quad \text{Eq 11}$$

Interquartile Range: IQR

First Quartile: Q_1

Third Quartile: Q_3

Paired t-test was used for statistical analysis while keeping a subject as a block. Confidence was set at 95%. To answer the hypotheses a, D2 and D3 are compared to show the acute KT application effectiveness. The effect of KT

application duration will be interpreted by the comparison with D3 to 24 hours, 48 hours, and 72 hours (D4 to D6). To explain hypothesis c (residual effect), D7 compared to D6 and D2 will be calculated to evaluate the residual effect.

One-sided Wilcoxon sign tests were utilized for hypotheses 1 and 2 to answer whether the KT will enhance the TTF or rate performance, because both performance data are not normally distributed. On the other hand, Hypothesis 3 investigated whether or not the KT would increase the sitting baseline. Therefore, one-tailed paired t-test (sitting baseline data passed the normality test) has been selected in this study. Hypotheses 4 and 5 were assessed using a two-tailed paired t-test (minimum rSO_2 and time to minimum rSO_2 level in the trial data had to pass the normality test) because it is expected that KT will affect muscle oxygenation, but the direction is not clear in the influence of minimum rSO_2 levels and time to minimum rSO_2 .

Chapter 3 Results

3.1 Fatiguing of Isotonic Knee Flexion Extension Exercise

3.1.1 Time to Fatigue (TTF):

Effects of KT were calculated by comparing the changes within TTF in the treatment and control leg of each subject across days of KT application.

Performance could have either increased or not increased (no change between days or decreased both days). A subject was considered to have enhanced performance if there was an increase in the TTF only within the treatment leg. Comparisons between D3 and D2 captured the acute effects of KT; whereas, comparisons between D3 and D4-D6 investigated the effects of duration of KT application.

In this study, an enhancement in the treatment leg's performance occurred in only 2 subjects (14%) between D3 and D2 (Table 5). Nine of the 14 subjects' (64%) performance either increased or not increased in both legs. The odds ratio (OR) of 0.75 (Figure 8) indicates that the odds of observing an increase in TTF is less for the treatment leg than the control leg. Furthermore, the results (Figure 9) show that the subjects did not experience a statistically significant increase in TTF upon immediate application of KT ($p=0.265$).

Table 5: Number of subjects in each TTF response category based on acute KT application

| Changes in TTF between D3 and D2 | Number of subjects |
|---|---------------------------|
| Increased in both legs | 5 |
| No increase in both legs | 4 |
| Treatment leg increased | 2 |
| Control leg increased | 3 |
| Total subjects | 14 |




Figure 8: Odds ratio for association between treatment and control leg and changes in TTF based on acute KT application




Figure 9: The acute effect of KT application on TTF in the treatment leg. ♦ indicates an outlier. * indicates statistical significance between median TTF (indicated by horizontal line within bar) for D2 and D3

The results for the duration of KT application are based on comparing leg performance between D3 and after 24 hours (D4), 48 hours (D5), and 72 hours (D6) of wearing KT (Figure 11). After 24 hours of KT application, within the treatment leg of 3 subjects, the TTF increased (21%). For 10 of 14 subjects (71%), the TTF either increased or not increased in both the treatment and control leg after 24 hours application of KT. No subject saw an enhancement only in the treatment leg 48 hours after KT application (D5). On this same day, similar performance (either increased or not increased) was noted for both legs in 86% of the subjects (12 of the 14 subjects). The results after 72 hours of KT application indicated that 9 of the subjects (64%) have a similar trend for both legs (either increased or not increased), and performance in 2 of the 14 subjects (14%) was better for the treatment leg but TTF decreased in the control leg. Table 6 quantifies the dose-response relationship between duration of KT application and leg performance. The relative risk shows that enhanced performance is more likely in the treatment leg only after 24 hours KT application (RR=1.286) (Figure 10). Statistical test results indicate no significant increase in TTF after 24 ($p=0.235$), 48 ($p=0.063$) or 72 hours ($p=0.139$) of KT application (Figure 11).

Table 6: Number of subjects in each TTF response category for each 24 hour period of KT application through D6 (72 hours after KT application)

| Changes in TTF from D3 | Number of subjects | | |
|--------------------------|--------------------|-----------|-----------|
| | D4-D3 | D5-D3 | D6-D3 |
| Increased in both legs | 6 | 9 | 6 |
| No Increase in both legs | 4 | 3 | 3 |
| Treatment leg increased | 3 | 0 | 2 |
| Control leg increased | 1 | 2 | 3 |
| Total subjects | 14 | 14 | 14 |




Figure 10: Relative risk for legs and changes in TTF based on the duration of KT application




Figure 11: Box plot of TTF throughout the duration of KT application in treatment leg. ♦ indicates an outlier. * indicates statistical significance between median TTF (indicated by horizontal line within bar) for D3 to D4, D5, D6

Days 7 and 8 (24 and 48 hours after KT removed) were tested to consider the residual effects of KT, if any. No residual effects of KT were expected. In other words, The TTF was expected to have a decrease at 24 hours after tape was removed (D7 compared to D6) and observe similar results as those on D2. In the treatment leg on D7 to D2 and D7 to D6, the TTF marked increase on both days (D7 to D2: $p=0.018$, Power=99.6%) (D7 to D6: $p=0.005$, Power=92.5%). However, when D7 is compared with D6, 10 of 13 subjects' (77%) TTF increase/decrease at the same time, and 3 of the subjects might increase because of KT residual effect. In comparison of D7 to D2, 12 of 13 subjects' (92%) TTF increased/decreased in both legs at the same time. Furthermore, 10 of 13 subjects (77%) show TTF increased on both legs when compared with D2 (Table 7). Additionally, the control leg was used to support if the increase found for the treatment leg was due to a residual effect. D7 to D6 control leg comparison has insignificant increase ($p=0.38$, Power=38.0%), but TTF on D7 significantly increased when compared to D2 ($p=0.005$, Power=100.0%) (Figure 12).

Table 7: Number of subjects in the category of TTF changes based on the residual of KT application results. D7 (the day after 24 hours KT removed) compare to D6 (The last day of test with KT application), D2 (A day before KT application wearing)

| Changes in TTF from D7 | Number of subjects | |
|--------------------------|--------------------|-----------|
| | D7-D6 | D7-D2 |
| Increased in both legs | 7 | 10 |
| No increase in both legs | 3 | 2 |
| Treatment leg increased | 3 | 0 |
| Control leg increased | 0 | 1 |
| Total subjects | 13 | 13 |




Figure 12: Box plot showing the TTF on D2, D6, and D7 for both the control and treatment leg. ♦ indicates an outlier. * indicates statistical significance between median TTF (indicated by horizontal line within bar) for D7 compare to D6 and D2 in treatment leg and control leg

The root cause of TTF increasing on D7 could be explained by comparing D2 to other days. The results indicate that both legs' TTF increased when extending the experiment day (Table 8). The most significant increase in treatment leg ($p=0.005$) and control leg ($p=0.003$) both happened on D5, which is also the day that both legs show the TTF significantly increased. Both the treatment leg and control leg results show that TTF significantly increased continuously from D5 to D8. According to the D2 comparison to other days' results, similar trends were shown in the treatment and control leg, and the time series could explain if the trend is caused by the learning effect.

Table 8: The results of Wilcoxon analysis in D2 (no KT effect) compare to D3 through D8 (the day with KT and after KT removed) to answer the residual effect of TTF is caused by KT or other factor.

| Compare to D2 | Treatment Leg | | | | Control Leg | | | |
|---------------|--------------------------|--------------|----------------|------------|--------------------------|--------------|----------------|-------------|
| | Median Difference in TTF | Range in TTF | <i>p-value</i> | Power | Median Difference in TTF | Range in TTF | <i>p-value</i> | Power |
| D3 | -2 | 20 | 0.265 | 33.6% | 1 | 33 | 0.550 | 7.0% |
| D4 | 3 | 15 | 0.062 | 76.5% | 5 | 20 | 0.265 | 63.1% |
| D5 | 10.5 | 28 | 0.005* | 99.6% ▲ | 11.5 | 35.5 | 0.003* | 100.0% ▲ |
| D6 | 13.5 | 61 | 0.021* | 89.6% ▲ | 14.25 | 79 | 0.004* | 94.8%▲ |
| D7 | 12 | 162 | 0.034* | 99.6% ▲ | 12 | 37 | 0.005* | 100.0% ▲ |
| D8 | 7 | 45 | 0.071 | 65.3% | 14 | 51.5 | 0.012* | 99.1%▲ |

* indicates statistical significance between median TTF.

▲ presents the Power is greater than 80%

Time series analysis is another method to show any potential learning effect. According to the Time Series Equation (Eq 8), coefficient β represents the slope of the trend. The slope describes whether or not the change between two legs is the same. In this study, the paired t-test of the estimated slope parameters results (data table please refer to appendices Table A- 5) indicate that the changes in TTF data have no significant increases when comparing the control leg and treatment leg ($p=0.165$). As a result, the time series' slopes show that two legs have similar performance during the long-term fatiguing exercise experiment.

3.1.2 Rate of Flexion/Extension:

The acute KT application result in raw data (Table 9) shows that 5 of the subjects' (36%) rate increase might have been because of KT application when compared with Day 2 (before KT application). Either the rate increased or not increased in both legs for 6 of 14 subjects (43%) upon immediate application of KT (D3 compared to D2). Despite the raw data group showing that only 36% of subjects

may enhance the rate by acute KT application, the OR was 1.8 (Figure 13). Figure 14 indicates that an increased rate was observed more in the treatment leg on D3 than in the control leg. The Wilcoxon test results (Figure 14) indicate a statistically significant increase in leg performance on Day 3 when compared to D2 ($p=0.027$), but note the low Power for this result.

Table 9: Number of subjects in each category of rate response based on acute KT application

| Changes in rate between D3 and D2 | Number of subjects |
|-----------------------------------|--------------------|
| Increased in both legs | 4 |
| No increase in both legs | 2 |
| Treatment leg increased | 5 |
| Control leg increased | 3 |
| Total subjects | 14 |




Figure 13: Odds ratio for association between treatment and control leg and changes in rate based on acute KT application




Figure 14: Box plot of the rate on D2 and D3 for both the treatment and control legs. ♦ indicates an outlier. * indicates statistical significance between median Rate (indicated by horizontal line within bar) for D2 and D3

Secondly, to assess the duration of KT application, Day 3 was selected to test the enhancement of rate after 24, 48, and 72 hours of KT application (Table 10). The rate increased in only the treatment leg of 1 subject 24 hours after KT application and either increased or not increased in both legs of 11 subjects (79%). After 48 hours of wearing KT, the rate increased in only the treatment leg for 2 of the 14 subjects (14%), and either increased or not increased in 8 of the subjects. A similar observation was noted 72 hours after KT application. Rate increased in the treatment leg in 2 subjects and either increased or not increased in 9 subjects. All the RR values are less than 1 (24 hours RR=0.875, 48 hours RR=0.818, 72 hours RR=0.89), indicating that an increased rate is less likely to occur in the treatment leg the longer the application of KT (Figure 15). These results are further supported by the Wilcoxon signed ranking test results (Figure 16). The subjects did not experience

a statistically significant rate increase in the duration of KT application (24 hours $p=0.556$, 48 hours $p=0.094$, 72 hours $p=0.201$).

Table 10: Number of subjects in each category of rate response for each 24 hour period of KT application through D6 (72 hours after KT application)

| Changes in rate from D3 | Number of subjects | | |
|--------------------------|--------------------|-----------|-----------|
| | D4-D3 | D5-D3 | D6-D3 |
| Increased in both legs | 6 | 7 | 6 |
| No increase in both legs | 5 | 1 | 3 |
| Treatment leg increased | 1 | 2 | 2 |
| Control leg increased | 2 | 4 | 3 |
| Total subjects | 14 | 14 | 14 |




Figure 15: Relative risk for legs and changes in rate based on the duration of KT application




Figure 16: Box plot of rate for D3, D4, D5, and D6. ♦ indicates an outlier. * indicates statistical significance between median Rate (indicated by horizontal line within bar) for D3 to D4, D5, D6

The residual effect was tested by D7 compared to D6 and D2. The raw data result on D7 compared to D6 was expected to show the rate increased continuously or retained the same rate as D6. Results were collected for 13 of the 14 subjects. Table 11 depicts the results for these 13 subjects. In comparison to D2, 9 of the 13 subjects (69%) show that the rate either increased or not increased in both legs and increased only in the treated leg for 3 of the 14 subjects (Table 11). The Wilcoxon signed ranking test results present that after taking off the KT for 24 hours, there was no significant increase observed in rate when compared to D6 ($p=0.447$), and the median difference being 0 tells that the rate on D7 is similar to D6. From another point of view, the result on D7 compared with D2 (Figure 17) not only shows the rate statistically significantly increased ($p=0.015$), but also has 88.0% of Power to support that the increase truly exists. Therefore, the control leg was used to measure

whether the KT had a residual effect in rate on treatment leg.

Table 11: Number of subjects in each change in rate category based on the residual of KT application results. D7 (the day after 24 hours KT removed) compare to D6 (The last day of test with KT application), D2 (A day before KT application wearing)

| Changes in rate from D7 | Number of subjects | |
|--------------------------|--------------------|-----------|
| | D7-D6 | D7-D2 |
| Increased in both legs | 3 | 7 |
| No increase in both legs | 3 | 2 |
| Treatment leg increased | 3 | 3 |
| Control leg increased | 4 | 1 |
| Total subjects | 13 | 13 |

The control leg D7 compare to D6 (Figure 17) shows that the increase is statistically insignificant, which is similar to the treatment leg. In comparison of D7 to D2, Wilcoxon signed ranking test result present that D7 has a significant increase. However, the Power shows that it only has 63.4% chance of an increase in rate as a result of residual effect. Therefore, D2 compared to other days is evidence to explain the changes between D2 through D7.




Figure 17 : Box plot of rate for D2, D6, and D7 for both the treatment and control leg. ♦ indicates an outlier. * indicates statistical significance between median rate (indicated by horizontal line within bar) for D7 compare to D6 and D2 in treatment leg and control leg

For D2 compared to other Days' results, both the treatment leg ($p=0.008$) and control leg ($p=0.018$) have the smallest p on D7. The treatment leg Power begins to be greater than 80% from D7 (Power=91.8%). Nevertheless, the control legs' largest Power is on D7 and is equal to 71.7%. According to the trends in the two legs, the rate is increasing every day (Table 12) for both. Hence, the last step is to show whether the rate increase is due to KT or another effect, and comparing the time series trends between legs could answer the question.

Table 12: The results of Wilcoxon analysis in D2 (no KT effect) compare to D3 through D8 (the day with KT and after KT removed) to answer the residual effect is caused by KT or other factor

| Rate on D2 compare to other Days | | | | | | | | |
|----------------------------------|---------------------------|--------------------------|----------------|--------|---------------------------|--------------------------|----------------|-------|
| Treatment Leg | | | | | Control Leg | | | |
| Day | Median Difference in rate | Range in rate difference | <i>p-value</i> | Power | Median Difference in rate | Range in rate difference | <i>p-value</i> | Power |
| D3 | 0.039 | 0.239 | 0.027* | 66.9% | 0.002 | 0.2 | 0.663 | 10.1% |
| D4 | 0.027 | 0.181 | 0.046* | 59.9% | 0.015 | 0.162 | 0.242 | 18.0% |
| D5 | 0.032 | 0.322 | 0.027* | 65.1% | 0.02 | 0.179 | 0.147 | 29.2% |
| D6 | 0.049 | 0.403 | 0.021* | 72.3% | 0.023 | 0.137 | 0.084 | 35.5% |
| D7 | 0.066 | 0.349 | 0.008* | 91.8%▲ | 0.044 | 0.127 | 0.033* | 63.4% |
| D8 | 0.095 | 0.376 | 0.008* | 93.3%▲ | 0.057 | 0.259 | 0.018* | 71.7% |

* indicates statistical significance between median rate

▲ presents the Power is greater than 80% and the p is truly significant

The same time series analysis that was performed on TTF was also done for rate. The time series analysis can assess if the treatment leg had better rate performance than the control leg. The results (data refer to appendices Table B- 5) show that there is an insignificant increase in rate ($p=0.741$). In addition, the Time Series' slope test shows that the two legs have similar performance during the long-term fatiguing exercise experiment.

3.2 Muscle Oxygenation

Every subject utilizes the muscles in a different way. In this study, 8 subjects have a rapid decrease in muscle oxygenation (rSO_2) for both legs at the beginning of the testing and slow recovery throughout the testing (Figure 34). The other subjects have a constant reduction in muscle oxygenation until the end of the trial.

3.2.1 Sitting baseline rSO_2 level:

Vastus Medialis (VM): The acute KT application result shows that 10 of 13

subjects (76.92%) had an increase in Sitting Baseline on D3 in comparison to D2 (Table 13). The OR=6.00 means that KT has a positive association with an increase in sitting baseline rSO₂ levels (Figure 18). The acute KT application did not significantly increase the sitting baseline rSO₂ levels on the treatment leg VM muscle (p=0.062) (Figure 19).

Table 13: Number of subjects in each category in VM muscle oxygenation sitting baseline based on acute KT application

| Changes in VM muscle sitting baseline between D3 and D2 | Number of subjects |
|---|--------------------|
| Increased in both legs | 5 |
| Decreased in both legs | 3 |
| Treatment leg increase | 5 |
| Control leg increased | 0 |
| Total subjects | 13 |




Figure 18: Odds ratio for association between the treatment and control leg VM muscles and changes in muscle oxygenation sitting baseline based on acute KT application




Figure 19: Box plot of VM sitting baseline rSO₂ levels for D2 and D3 in the treatment leg. ♦ indicates an outlier. * indicates statistical significance between mean sitting baseline (indicated by horizontal line within bar) for D2 and D3

Analysis regarding the duration of KT application (Table 14) revealed that 8 subjects' sitting baseline levels decreased on D4 from D3. By D5, 11 subjects' sitting baseline decreased (78.57%) from D3, but on D6 the subjects who decreased their sitting baseline went down to 10 (71.43%). Additionally, the RR provides evidence that extending the duration of KT application might not increase the sitting baseline rSO₂ levels, since the values are all less than 1 (D4-D3 RR=0.857, D5-D3 RR=0.333, D6-D3 RR=0.4) (Figure 20). Insignificant increases in treatment leg VM muscle sitting baseline (Figure 21) were observed when D3 was compared with other taped days (24 hours $p=0.884$, 48 hours $p=0.993$, 72 hours $p=0.806$). In addition, RR and mean difference in paired t-test results all show that the longer duration will decrease the sitting baseline rSO₂ levels in VM (RR all <1, mean difference <0).

Table 14: Number of subjects in each category of VM muscle sitting baseline response for each 24 hours period of KT application through D6 (72 hours after KT application)

| Changes in VM muscle sitting baseline from D3 | Number of subjects | | |
|---|--------------------|-----------|-----------|
| | D4-D3 | D5-D3 | D6-D3 |
| Increased in both legs | 3 | 2 | 3 |
| Not increased in both legs | 4 | 4 | 3 |
| Treatment leg increase | 3 | 1 | 1 |
| Control leg increased | 4 | 7 | 7 |
| Total subjects | 14 | 14 | 14 |




Figure 20: Relative risk for legs and changes in muscle oxygenation sitting baseline based on the duration of KT application




Figure 21: Box plot of VM muscle oxygenation sitting baseline for D3, D4, D5, D6. ♦ indicates an outlier. * indicates statistical significance between mean muscle oxygenation sitting baseline (indicated by horizontal line within bar) for D3 to D4, D5, D6

The residual effect from KT can be observed by analyzing D7. On D7, 9 of the subjects had both legs either increase the sitting baseline levels or did not increase their levels in comparison to D6 (Table 15). The comparison between D6 and D7 shows insignificant increase ($p=0.399$) (Figure 22). Furthermore, there is no statistical difference between D7 compared with D2, which shows there is no residual effect ($p=0.399$).

Table 15: Number of subjects in each category of VM muscle oxygenation sitting baseline changes based on the residual of KT application results. D7 (the day after 24 hours KT removed) compare to D6 (The last day of test with KT application), D2 (A day before KT application wearing)

| Changes in VM muscle sitting baseline from D7 | Number of subjects | |
|---|--------------------|-----------|
| | D7-D6 | D7-D2 |
| Increased in both legs | 4 | 2 |
| Not increased in both legs | 5 | 3 |
| Treatment leg increase | 3 | 3 |
| Control leg increased | 1 | 4 |
| Total subjects | 13 | 12 |




Figure 22: Box plot of VM sitting baseline muscle oxygenation for the treatment legs on D2, D6, and D7. ♦ indicates an outlier. * indicates statistical significance between mean VM muscle oxygenation sitting baseline (indicated by horizontal line within bar) for D7 compare to D6 and D2 in treatment leg VM muscles

Vastus Lateralis (VL): The results from acute KT application on D3 shows that 9 of 14 subjects (69%) increase or did not increase in both of their legs at the same time in comparison to D2. 23% of subjects VL sitting baseline increased from D2 only on the treatment leg (Table 16). The OR indicates that the acute KT application is associated with VL sitting baseline increase (OR=2.13) (Figure 23). The comparison of D3 to D2 in treatment leg VL muscle shows that there is a statistically significant increase in sitting baseline rSO₂ levels with acute KT application ($p=0.045$), but the Power of the test shows only 64.155% chance of an increase in VL sitting baseline as a result of acute KT application (Figure 24, Table C- 4).

Table 16: Number of subjects in each category of VL muscle oxygenation sitting baseline changes based on acute KT application

| Changes in VL muscle sitting baseline between D3 and D2 | Number of subjects |
|---|--------------------|
| Increased in both legs | 5 |
| Not increased in both legs | 4 |
| Treatment leg increased | 3 |
| Control leg increased | 1 |
| Total subjects | 13 |




Figure 23: Odds ratio for association between treatment and control leg and changes in VL muscle oxygenation sitting baseline based on acute KT




Figure 24: Box plot of VL muscle oxygenation sitting baseline for D2 and D3 in the treatment leg. ♦ indicates an outlier. * indicates statistical significance between mean sitting baseline (indicated by horizontal line within bar) for D2 and D3

The effect of duration of KT application shows that after 24 hours of KT application, 6 of 14 subjects (43%) VL sitting baseline increased only on the treatment leg. After wearing KT for 48 hours, 10 of the subjects (71%) increase/did not increase their sitting baseline levels in both legs at the same time. After 72 hours KT application, 5 subjects (36%) increased only on the treatment leg, and 4 subjects (29%) only increase in the control leg. RR results show that all the values are greater than 1, which means that KT application has positive association with VL increasing sitting baseline levels (Figure 25). However, the RR consistently decreases from 24 hours to 72 hours (24 hours RR=1.8, 48 hours RR=1.286, 72 hours RR=1.14) showing that the duration of KT application reduces this association between KT and VL sitting baseline. The duration of KT application results (Figure 26) show no statically significance increase after 24 ($p=0.622$), 48 ($p=0.724$), and 72 hours

($p=0.600$) KT application.

Table 17: Number of subjects in each category of VL muscle oxygenation sitting baseline changes for each 24 hours period of KT application through D6 (72 hours after KT application)

| Changes in VL muscle sitting baseline from D3 | Number of Subjects | | |
|---|--------------------|-----------|-----------|
| | D4-D3 | D5-D3 | D6-D3 |
| Increased in both legs | 3 | 6 | 3 |
| Not increased in both legs | 3 | 4 | 2 |
| Treatment leg increased | 6 | 3 | 5 |
| Control leg increased | 2 | 1 | 4 |
| Total subjects | 14 | 14 | 14 |




Figure 25: Relative risk for legs and changes in TTF based on the duration of KT application




Figure 26: Box plot of VL muscle oxygenation sitting baseline for D3, D4, D5, D6. ♦ indicates an outlier. * indicates statistical significance between mean muscle oxygenation sitting baseline (indicated by horizontal line within bar) for D3 to D4, D5, D6

D7 compare to D6 and D2 can define the residual effect of KT application. According to D7 compared to D6, 10 of 13 subjects (77%) had both of their legs either increase or did not increase their VL sitting baseline level (Table 18). Only 1 of the subjects shows a residual effect, with the treatment leg increasing VL sitting baseline level from D6. When D7 is compare to D2, half of the subjects simultaneously increased or did not increased their sitting VL baseline rSO₂ levels for both legs. 4 of the subjects (31%) had a residual effect from KT application because only the treatment leg increased on D7. There were no statistically significant changes between D7 and D2 as well as between D7 and D6 for VL sitting baseline rSO₂ levels ($p= 0.311$; $p=0.184$) (Figure 27).

Table 18: Number of subjects in each category of VL muscle oxygenation sitting baseline changes based on the residual of KT application results. D7 (the day after 24 hours KT removed) compare to D6 (The last day of test with KT application), D2 (A day before KT application wearing)

| Changes in VL muscle sitting baseline from D7 | Number of subjects | |
|---|--------------------|-----------|
| | D7-D6 | D7-D2 |
| Increased in both legs | 5 | 4 |
| Not increased in both legs | 5 | 2 |
| Treatment leg increased | 1 | 4 |
| Control leg increased | 2 | 2 |
| Total subjects | 13 | 12 |




Figure 27: Box plot of treatment leg VM muscle oxygenation sitting baseline for D2, D6, and D7. ♦ indicates an outlier. * indicates statistical significance between mean VM muscle oxygenation sitting baseline (indicated by horizontal line within bar) for D7 compare to D6 and D2 in treatment leg VM muscles

3.2.2 Minimum rSO₂ level:

Vastus Medialis (VM): The results for acute KT application shows that 4 subjects (31%) had changes in minimum rSO₂ levels between D3 and D2 in different directions for both of their legs. 9 of 13 subjects (69%) had VM minimum rSO₂ levels increased/decreased in both legs (Table 19). The paired t-test results show that the

subjects experienced a statistically significant change in the VM minimum rSO₂ levels immediately after putting on the KT ($p=0.022$) (Figure 28).

Table 19: Number of subjects in each category of VM minimum rSO₂ levels changes based on acute KT application

| Changes in VM minimum rSO ₂ levels between D3 and D2 | Number of subjects |
|---|--------------------|
| Increased in both legs | 6 |
| Decreased in both legs | 3 |
| Treatment leg increased | 3 |
| Control leg increased | 1 |
| Total subjects | 13 |




Figure 28: Box plot of VM muscles of minimum rSO₂ levels on D2 and D3 for both the treatment and control leg. ♦ indicates an outlier. * indicates statistical significance between mean minimum rSO₂ levels (indicated by horizontal line within bar) for D2 and D3.

After 24 hours KT application, 7 subjects (54%) showed that the treatment and control leg either increase or decrease in opposite directions for their VM minimum rSO₂ levels, and 2 of the subjects had increases for the treatment leg, and the other 3 subjects show that KT will decreased the VM minimum rSO₂ levels for the treatment leg. After 48 hours 7 of 14 subjects (50%) show that minimum rSO₂

increases for one leg and decreases for their other leg. 5 of those subjects had an increase in minimum rSO₂ levels for the treatment leg. After 72 hours of wearing KT, 10 subjects (71%) had their control and treatment leg minimum rSO₂ levels change in different directions when compared to D3 (Table 20). The paired t-test results demonstrate that the duration of KT application will not change the effect of KT on minimum rSO₂, 24 ($p=0.384$), 48 ($p=0.241$), 72 hours ($p=0.741$) (Figure 29).

Table 20: Number of subjects in each category of VM minimum rSO₂ changes for each 24 hours period of KT application through D6 (72 hours after KT application)

| Changes in VM minimum rSO ₂ levels from D3 | Number of subjects | | |
|---|--------------------|-----------|-----------|
| | D4-D3 | D5-D3 | D6-D3 |
| Increased in both legs | 3 | 2 | 2 |
| Decreased in both legs | 4 | 5 | 2 |
| Treatment leg increased | 2 | 5 | 4 |
| Control leg increased | 3 | 2 | 5 |
| No change | 1* | 0 | 1** |
| Total subjects | 13 | 14 | 14 |

* control leg VM minimum rSO₂ levels no change, treatment leg VM minimum rSO₂ levels increased

** control leg VM minimum rSO₂ levels decreased, treatment leg VM minimum rSO₂ levels no change




Figure 29: Box plot of VM minimum rSO₂ levels in the treatment leg for D3, D4, D5, and D6. ♦ indicates an outlier. * indicates statistical significance between mean minimum rSO₂ levels (indicated by horizontal line within bar) for D3 to D4, D5, D6

The residual effect was checked by D7 compare to D2 and D6. In the raw data grouping result, none of subject has no change between days. 7 of the subjects (54%) might experience the KT residual effect 24 hours after removal. When comparing D7 to D2, 5 subjects (42%) have residual possible effect (Table 21). Nevertheless, the paired t-test results show that the minimum rSO₂ have insignificant differences between D7 and D2 ($p=0.215$). The D7 and D6 comparison also presents that insignificant change was discovered between the two days ($p=0.314$) (Figure 30). The results all indicate that KT will not have residual effect in minimum rSO₂ levels 24 hours after removal.

Table 21: Number of subjects' in each category of VM minimum rSO₂ changes based on the residual of KT application results. D7 (the day after 24 hours KT removed) compare to D6 (The last day of test with KT application), D2 (A day before KT application wearing)

| Changes in VM minimum rSO ₂ levels from D7 | Number of Subjects | |
|---|--------------------|-----------|
| | D7-D6 | D7-D2 |
| Increased in both legs | 2 | 4 |
| Decreased in both legs | 4 | 3 |
| Treatment leg increased | 2 | 2 |
| Control leg increased | 5 | 3 |
| Total subjects | 13 | 12 |




Figure 30: Box plot of the treatment leg VM minimum rSO₂ levels on D2, D6, D7. ♦ indicates an outlier. * indicates statistical significance between mean VM minimum rSO₂ levels (indicated by horizontal line within bar) for D7 compare to D6 and D2 in treatment leg VM muscles

Vastus Lateralis (VL): The immediate KT application does not show a difference in raw data grouping results, because 9 of the subjects (69%) increase/decrease the VL minimum rSO₂ in both legs (Table 22). The acute KT application does not show a significant difference ($p=0.182$) in the VL minimum rSO₂ levels (Figure 31).

Table 22: Number of subjects in each category of changes in VM minimum rSO₂ levels based on acute KT application

| Changes in VL minimum rSO ₂ levels between D3 and D2 | Number of subjects |
|---|--------------------|
| Increased in both legs | 7 |
| Decreased in both legs | 2 |
| Treatment leg increased | 3 |
| Control leg increased | 1 |
| Total | 13 |




Figure 31: Box plot of the treatment leg VL minimum rSO₂ levels for D2 and D3. ♦ indicates an outlier. * indicates statistical significance between mean minimum rSO₂ levels (indicated by horizontal line within bar) for D2 and D3

Secondly, the duration of KT application effectiveness were examined by D3 compared with D4 through D6. When D4 is compared to D3, 10 of the subjects (77%) increase/decrease VL minimum rSO₂ levels in both legs. After 48 hours KT application, 50% of subjects' treatment leg VL minimum rSO₂ changed differently from the control leg. When D6 is compared to D3, 10 subjects (71%) had the minimum rSO₂ levels increase/decrease in both legs (Table 23). According to the

raw data grouping, the duration effect of KT application cannot be explained. Furthermore, the paired t-test results show that no significant difference was discovered in 24 ($p=0.297$), 48 ($p=0.379$), or 72 hours ($p=0.321$) after KT application (Figure 32).

Table 23: Number of subjects in each category of changes in VL minimum rSO₂ levels for each 24 hours period of KT application through D6 (72 hours after KT application)

| Changes in VL minimum rSO ₂ levels from D3 | Number of subjects | | |
|---|--------------------|-------|-------|
| | D4-D3 | D5-D3 | D6-D3 |
| Increased in both legs | 3 | 2 | 6 |
| Decreased in both legs | 7 | 5 | 4 |
| Treatment leg increased | 1 | 4 | 1 |
| Control leg increased | 2 | 3 | 3 |
| Total | 13 | 14 | 14 |




Figure 32: Box plot of VL minimum rSO₂ levels in the treatment leg for D3, D4, D5, and D6. ♦ indicates an outlier. * indicates statistical significance between mean minimum rSO₂ levels (indicated by horizontal line within bar) for D3 to D4, D5, D6

D7 comparison could explain the KT residual effect. The raw data show that 7 subjects (54%) might have a residual effect since the two legs changed in different ways. Nevertheless, since the same numbers of subjects were found to have the treatment leg and control leg minimum rSO₂ value change in the same directions, the residual effect may not exist. The paired t-test between D7 and D2 shows that the two days values are statistically insignificantly different ($p=0.820$). The result for D7 compared to D6 also shows that VL minimum rSO₂ levels have insignificant differences ($p=0.125$).

Table 24: Number of subjects in each category of changes in VL minimum rSO₂ levels based on the residual of KT application results. D7 (the day after 24 hours KT removed) compare to D6 (The last day of test with KT application), D2 (A day before KT application wearing)

| Changes in VM minimum rSO ₂ levels from D7 | Number of Subjects | |
|---|--------------------|-----------|
| | D7-D6 | D7-D2 |
| Increased in both legs | 2 | 3 |
| Decreased in both legs | 4 | 2 |
| Treatment leg increased | 1 | 1 |
| Control leg increased | 5 | 6 |
| No change | 1* | 0 |
| Total subjects | 13 | 12 |

*control leg minimum rSO₂ levels no change, treatment leg minimum rSO₂ levels decreased




Figure 33: Box plot of treatment leg VL minimum rSO₂ levels for D2, D6, and D7. ♦ indicates an outlier. * indicates statistical significance between mean VL minimum rSO₂ levels (indicated by horizontal line within bar) for D7 compare to D6 and D2 in treatment leg VL muscles

An example of muscle oxygenation over a trial is shown in Figure 34 for the treatment leg of subject 5 on D3. The rSO₂ level for the VL muscle drops rapidly at the beginning of the trial and then starts to recover. The VM muscle minimum rSO₂ levels are greater than the VL, which presents a comparative analysis for the minimum drop in rSO₂ levels for both muscle (VL and VM) in the taped and control legs respectively. VL rSO₂ levels always drop more than in the VM.




Figure 34: Example of muscle oxygenation trial (Subject 5, treatment leg, on D3)

3.2.3 Time to minimum rSO₂ level:

Vastus Medialis (VM): The acute KT application might influence the treatment leg VM time to minimum rSO₂, because 8 of 13 subjects (62%) show that the treatment leg changes differently from the control leg. Except for 1 subject who had no change in the treatment leg, 4 of the subjects have positive/negative changes simultaneously on both legs, and 4 of the subjects had an increase in the treatment leg, but a decrease in the control leg; and another 4 subjects decreased in the treatment leg, but had an increase in the control leg (Table 25). The treatment leg paired t-test result has no statistically significant difference to explain that the acute KT application will change the time to minimum rSO₂ ($p=0.609$) (Figure 35).

Table 25: Number of subjects in each category of changes in VM time to minimum rSO₂ based on acute KT application

| Changes in VM time to minimum rSO ₂ levels between D3 and D2 | Number of Subjects |
|---|--------------------|
| Increased in both legs | 3 |
| Decreased in both legs | 1 |
| Treatment leg increased | 4 |
| Control leg increased | 4 |
| No change | 1* |
| Total subjects | 13 |

* control leg time to minimum rSO₂ levels decreased, treatment leg time to minimum rSO₂ levels no change




Figure 35: Box plot of treatment leg VM time to minimum rSO₂ levels for D2 and D3. ♦ indicates an outlier. * indicates statistical significance between mean time to minimum rSO₂ levels (indicated by horizontal line within bar) for D2 and D3

Despite the acute KT application having no significant effect in VM time to minimum rSO₂ levels, the duration of KT application may still cause a change. Based on the raw data after 24 hours of KT application, 9 of the subjects (64%) increase/decrease simultaneously in both legs. 48 hours of KT application has 8 of

14 subjects (57%) both legs increase/decrease. And 72 hours of KT application shows 7 subjects (50%) time to minimum rSO₂ in the two legs increase/decrease together (Table 26). Furthermore, the duration of KT application comparison results show no statistically significant differences between acute KT application and other KT application days (24 hours $p=0.613$, 48 hours $p=0.326$, 72 hours $p=0.253$). After 48 hours of KT application, the time to minimum rSO₂ levels does occur earlier (mean difference =-0.062).

Table 26: Number of subjects in each category of changes in VM time to minimum rSO₂ levels for each 24 hours period of KT application through D6 (72 hours after KT application)

| Changes in VM time to minimum rSO ₂ levels from D3 | Number of subjects | | |
|---|--------------------|-----------|-----------|
| | D4-D3 | D5-D3 | D6-D3 |
| Increased in both legs | 4 | 3 | 3 |
| Decreased in both legs | 5 | 5 | 4 |
| Treatment leg increased | 3 | 2 | 4 |
| Control leg increased | 1 | 4 | 1 |
| No change | 0 | 0 | 1* 1** |
| Total subjects | 13 | 14 | 14 |

* control leg time to minimum rSO₂ levels decreased, treatment leg time to minimum rSO₂ levels no change

** control leg time to minimum rSO₂ levels increased, treatment leg time to minimum rSO₂ levels no change




Figure 36: Box plot of VM time to minimum rSO₂ for D3, D4, D5, and D6. ♦ indicates an outlier. * indicates statistical significance between mean VM time to minimum rSO₂ levels (indicated by horizontal line within bar) for D3 to D4, D5, D6

When D7 is compared to D6, the results explain the residual effect. Table 27 shows that only 3 subjects might have a residual effect, because all the other subjects (77%) increase/decrease in both legs (7 subjects) or have no change in the treatment leg (3 subjects). When the results from 24 hours after KT removal are compared to before KT application, 5 of 12 subjects (42%) VM time to minimum rSO₂ increase/decrease in both legs. 6 of 12 subjects (50%) increase/decrease oppositely between the two legs, but 5 subjects have time to minimum rSO₂ delayed in treatment leg and a shift to an earlier time in the control leg. The paired t-test results show that D2 (p=0.332) and D6 (p=0.826) both have no statically significant difference with D7 (Figure 37). Hence, the residual effect from KT doesn't exist.

Table 27: Number of subjects in each category of changes in VM time to minimum rSO₂ levels based on the residual of KT application results. D7 (the day after 24 hours KT removed) compare to D6 (The last day of test with KT application), D2 (A day before KT application wearing)

| Changes in VM time to minimum rSO ₂ levels from D7 | Number of subjects | |
|---|--------------------|-----------|
| | D7-D6 | D7-D2 |
| Increased in both legs | 3 | 3 |
| Decreased in both legs | 4 | 2 |
| Treatment leg increased | 1 | 5 |
| Control leg increased | 2 | 1 |
| No change | 2* 1** | 1* |
| Total subjects | 13 | 12 |

* control leg time to minimum rSO₂ levels decreased, treatment leg time to minimum rSO₂ levels no change

** both legs time to minimum rSO₂ levels no change




Figure 37: Box plot of the treatment leg VM time to minimum rSO₂ levels for D2, D6, and D7. ♦ indicates an outlier. * indicates statistical significance between mean VM time to minimum rSO₂ levels (indicated by horizontal line within bar) for D7 compare to D6 and D2 in treatment leg VM muscles

Vastus Lateralis (VL): Table 28 shows that 8 of the subjects (62%) did not increase/decrease simultaneously in two legs after the acute KT application.

Nevertheless, 4 of 8 subjects have time to minimum rSO₂ increased, and the others

are decreased. Therefore, two-sided paired t-test was chosen for analysis. The result shows no statistically significant difference between D2 and acute KT application ($p=0.814$).

Table 28: Number of subjects in each category of changes in VM time to minimum rSO₂ levels based on acute KT application

| Changes in VL minimum rSO ₂ levels between D3 and D2 | Number of subjects |
|---|--------------------|
| Increased in both legs | 2 |
| Decreased in both legs | 3 |
| Treatment leg increased | 4 |
| Control leg increased | 4 |
| Total subjects | 13 |




Figure 38: Box plot of the treatment leg VL time to minimum rSO₂ levels for D2 and D3. ♦ indicates an outlier. * indicates statistical significance between mean time to minimum rSO₂ levels (indicated by horizontal line within bar) for D2 and D3

VM (Table 26) and VL (Table 29) have almost the same number of subjects in each group after 24 hours of KT application. Similarly, after 72 hours of KT

application, VM and VL have almost the same number of subjects in the same group as well. After 48 hours, for the VL muscle, 11 of 14 subjects (79%) indicate that KT will not change the time to minimum rSO₂ levels when compared to acute KT application and 48 hours of KT application. The duration of KT application results from 24 ($p=0.063$), 48 ($p=0.367$), and 72 hours ($p=0.529$) show that the subjects did not experienced a statistically significant difference in time to minimum rSO₂ levels after applying the KT.

Table 29: Number of subjects in each category of changes in VL time to minimum rSO₂ levels for each 24 hours period of KT application through D6 (72 hours after KT application)

| Changes in VL time to minimum rSO ₂ levels from D3 | Number of subjects | | |
|---|--------------------|-----------|-----------|
| | D4-D3 | D5-D3 | D6-D3 |
| Increased in both legs | 4 | 6 | 4 |
| Decreased in both legs | 5 | 5 | 4 |
| Treatment leg increased | 2 | 2 | 4 |
| Control leg increased | 2 | 0 | 1 |
| No change | 0 | 1** | 1** |
| Total subjects | 13 | 14 | 14 |

* control leg time to minimum rSO₂ levels decreased, treatment leg time to minimum rSO₂ no change

** treatment leg time to minimum rSO₂ decreased, control leg time to minimum rSO₂ no change




Figure 39: Box plot of VL time to minimum rSO₂ levels for D3, D4, D5, and D6 in treatment leg. ♦ indicates an outlier. * indicates statistical significance between mean time to minimum rSO₂ levels (indicated by horizontal line within bar) for D3 to D4, D5, D6

After removing the KT for 24 hours, 8 subjects (62%) show that the treatment leg increases/decreases differently from the control leg, However, 4 of 8 subjects time to minimum rSO₂ increased, and the other 4 subjects decreased, which cannot demonstrate that KT has a residual effect in time to minimum rSO₂ levels. When D7 is compared to D2, 67% of subjects' time to minimum rSO₂ in both legs changed simultaneously (Table 30). Moreover, the paired t-test results (Figure 40) interpret that no significant difference were found when comparing D7 to before KT application ($p=0.626$) and after 72 hours of KT application ($p=0.201$). the residual effect from KT does not exist due to the D7 comparison to before KT application and after 72 hours of KT application results.

Table 30: Number of subjects' in each category of changes in VL time to minimum rSO₂ levels based on the residual of KT application results. D7 (the day after 24 hours KT removed) compare to D6 (The last day of test with KT application), D2 (A day before KT application wearing)

| Changes in VM minimum rSO ₂ levels from D7 | Number of subjects | |
|---|--------------------|-------|
| | D7-D6 | D7-D2 |
| Increased in both legs | 1 | 2 |
| Decreased in both legs | 4 | 6 |
| Treatment leg increased | 3 | 2 |
| Control leg increased | 3 | 1 |
| No change | 1* 1** | 1*** |
| Total | 13 | 12 |

* treatment leg time to minimum rSO₂ levels decreased, control leg time to minimum rSO₂ levels no change

** treatment leg time to minimum rSO₂ levels increased, control leg time to minimum rSO₂ levels no change

*** control leg time to minimum rSO₂ levels decreased, treatment leg time to minimum rSO₂ levels no change




Figure 40: Box plot of the treatment leg VL time to minimum rSO₂ levels for D2, D6, and D7♦ indicates an outlier. * indicates statistical significance between mean VL time to minimum rSO₂ levels (indicated by horizontal line within bar) for D7 compare to D6 and D2 in treatment leg VL muscles

Overall, the results demonstrate the changes and trends from D2 to D7. The TTF and rate results indicate that significant change is not due to KT, but from another factor. The muscle oxygenation results show that KT can change the rSO_2 level. The reason for this is that the rSO_2 level significantly changes only occurred on the treatment leg during days with KT application. The changes in muscle oxygenation in VL and VM have different influences from KT application. Even though the VM muscle has some significant changes from KT in the sitting baseline result, VL had larger changes. However, in the minimum rSO_2 level comparison, VM has significantly smaller rSO_2 levels during KT application (D2 to D3), but no obvious changes occur in the VL muscle. The implications of these results will be explored in the discussion chapter.

Chapter 4 Discussion

The aim of this research project was to assess Kinesio Tape application effectiveness on isotonic fatiguing knee flexion/extension exercise. The results revealed that the application of KT to the knee joint does not enhance the performance of the knee in terms of TTF, rate or muscle oxygenation level in healthy subjects. Nevertheless, during the eight days of testing some delays in TTF, enhancements in rate of flexion/extension, and change in muscle oxygenation were observed in both legs – the leg that KT was applied to for 4 days and the control leg.

4.1 Fatiguing of Isotonic Knee Flexion Extension Exercise

4.1.1 Time to Fatigue (TTF): As a part of this research study it was hypothesized that KT application would delay the TTF during knee the flexion/extension isotonic exercise. Based on the results of the study the hypothesis cannot be supported. The reason is that the OR of D3 compared to D2 is equal to 0.75. The fact that acute KT application will not increase the TTF was supported by the Wilcoxon signed ranking test, OR, and the raw data. Secondly, the lack of a KT application duration effect on increasing the TTF was supported by the RR from 24 hours KT application to 72 hours KT application and the statistic results. Furthermore, the raw data shows that during the KT application, there are always 64% to 86% of subjects whose results suggest that KT is not the main factor to enhance the TTF. Thirdly, the KT residual effect in TTF was not discovered in this study. Even though the treatment leg result on D7 compared to D6 and D2 both indicate that the TTF still increases after removal of KT, the control leg results provide evidence that the effect is not from KT residual. Overall, the results suggest that the TTF performance increase observed over time in the current study was the

results of effects other than the KT.

Unlike the findings of the Knapman et al. (2016) study that showed healthy subjects' enhancement of the maximal extension peak torque in isokinetic exercise on lumbar due to KT application, this case-control study findings cannot support that the enhancement of the performance of a knee flexion/extension isotonic exercise protocol can be attributed to KT. The comparison of the treatment leg to the control leg provides important evidence that, based on the current results, the improvements could be attributed to a "learning effect" from the exercise performance over multiple days, rather than KT application. Poon (2014), in a review of isokinetic performance papers, states that observed changes in performance could be a placebo effect. In the TTF data there were no subjects for which the treatment leg TTF increased without a corresponding increase in control leg TTF. Therefore, it appears that no placebo effect was found in the TTF data when looking at the raw data. Moreover, TTF for 5 of 13 subjects increased consistently for both legs every day, which indicates a learning effect may have existed (K. Jackson et al., 2016; J.T. Han et al., 2014; C. Fahs et al., 2015).

4.1.2 Rate of Flexion/Extension: The results concerning hypothesis 2 show that the rate changed over time, but there was no evidence that the increase in rate was caused by KT application. The enhancements due to acute KT application were shown in the treatment leg in D3 compared to D2 ($p=0.027$) and OR (1.8), but the Power shows only a 66.93% chance that an increase of rate is actually due to the acute KT application. Therefore, increasing the number of subjects is needed in a follow-up study. However, the leg comparison for D3 to D2 shows that the difference

in treatment leg was not significantly different from the control leg ($p=0.11$), which suggests that the increase in treatment leg was not due to the acute KT application. The duration of KT application was proven to have negative effect after 24, 48, and 72 hours by RR result, and the Wilcoxon signed ranking test also provides that no significant increase showed from extending the duration of KT application. The residual effect did not exist in the rate results, although the result in D7 compare to D2 shows a statistically significant increase. However, the control leg comparison and D2 compared to other days both support that the two legs have similar rate results, and the rate in both legs show increases. The time series result support the statement that the rate increase is caused by learning effect, because the difference trends between two legs are statistically insignificant.

Time series theory provides additional learning effect evidence. According to the number of subjects whose TTF and rate increased by the day factor, it is possible that most of the subjects enhanced their performance by practicing. However, some of the subjects have a negative coefficient in the time series. This result suggests that the relationship between TTF and rate be investigated. All the negative coefficients (β) in TTF or rate have a positive coefficient (β) on the opposite side (Table A- 5, Table B- 5). As a result, TTF decreases are caused by increasing rate (frequency). In contrast, a negative rate coefficient corresponds to a positive coefficient in TTF. Nevertheless, learning effect was also defined by the case and control leg time series comparison, TTF and rate both show that the treatment leg's performance is similar to the control leg.

Subject 12 has a lower TTF time series coefficient, but has the highest rate time series' coefficient in both legs. The questionnaire provides evidence that the subject began to change his exercise strategy on D4, which is also a day after he

participated in high intensity sports. From D4 to D7, subject 12 TTF increased consistently. On the other hand, 3 of the subjects' control leg and 4 of the subjects' treatment leg have a negative coefficient (β) in the TTF time series result (Eq 6). However, when examining the rate time series, the TTF decrease could be explained by subjects increasing the rate after D2. None of the subjects had TTF and rate response with negative coefficients at the same time in the time series, which indicates that subjects learned to perform better in TTF or rate.

A previous study mentioned that English soccer players will have different muscle strength and flexibility on the dominant and non-dominant legs, which is because the training that soccer players undergo are more focused on the dominant leg (Rahnama, 2005). Overall, in this study, the TTF and rate results both indicate that learning effect is the main cause of performance enhancement. It is clear that for TTF and rate there is no significant change in performance due to KT application or after its removal, which goes against some of the KT manufacturers' claims about performance enhancement (Hypothesis 1 & Hypothesis 2). In another point of view, the treatment leg and control leg results also provide evidence to show that in fatiguing isotonic flexion/extension exercise, the two legs TTF and rate performance are similar. A prior project assessed a balance leg training that was able to decrease the asymmetry between two legs in young tennis players (I. Sannicandro, 2014). Another study assessed that runners have similar performance in stride length (K. Maćkała, 2010), ground contact time (P.W. Wong, 2008), unilateral squat strength, and weight bearing stance (K. McCuedy, 2005) in both legs. The study shows that subjects who are runners or basketball players will have leg symmetry due to balanced leg training, which could eliminate the concerns in this study that 50% of the subjects have running/biking/basketball exercise habits.

4.1.3 Grouping

When looking at the data broadly, the results show that a learning effect is present, but also that some subjects improve less after KT application, and some of the subjects have more random changes in performance. This section discusses the category and classifies method results.

First, none of the subjects' TTF and rate decrease at the same time in the time series analysis. Secondly, all the negative TTF coefficient values in the time series match with a positive coefficient in the rate time series results, and vice versa. Therefore, summarizing the result from the questionnaire, raw data, and time series analysis, subjects could be classified into three different groups (a) Learning, (b) Placebo (González-Iglesias, 2009; Poon, 2014), and (c) rate control. According to the TTF and rate result, 5 of the subjects can be classified as learning effect, because the raw data increases by days, and the time series coefficients (β) are positive in TTF and rate (Table 31). A second group of subjects are classified due to the questionnaire results which indicate that those subjects believe that KT enhanced their performance. However, when examining the performance data for these subjects, (1) only a few subjects enhanced their performance during KT application, which means the KT did not actually improve subject performance, and (2) some subjects' performances are randomly varied, or always increasing, even after removal of the KT (for instance: S7, S8) (Table 31). Therefore, Subject 7 and Subject 8 were classified in both the learning and placebo groups. The third group were categorized by checking the TTF and rate result at the same time. 5 of the subjects' performance changed randomly from D2 through D7. However, when the TTF decreased, an increasing rate was found in the result, and the endurance and rate are correlated. As a result, the performance is not only related to learning effect,

but also associated with the rate changing. Nevertheless, the control leg and treatment leg show no dramatic difference between one another, which also indicates that the TTF performance changed by subjects' body decreases or increases by the rate, not by KT.

Table 31: Subjects grouped by learning effect, placebo effect, and rate control effect

| Learning | Placebo | Rate Control |
|----------|---------|--------------|
| S3 | S1 | S5 |
| S4 | S2 | S6 |
| S7 | S7 | S11 |
| S8 | S8 | S12 |
| S10 | S9 | S14 |
| | S13 | |

4.2 Muscle Oxygenation

It was hypothesized that the use of KT would change the leg muscle sitting baseline rSO_2 level (Hypothesis 3), rSO_2 minimum levels (Hypothesis 4) and the time to minimum rSO_2 level (Hypothesis 5). The manufacturers claim that KT will increase the blood flow and muscle oxygenation. The results of this research evaluate the truth of those claims.

4.2.1 Sitting Baseline rSO_2 level:

The manufacturer explained and believed that the skin was stretched back by KT (KT, Rock tape website). Therefore, KT not only increases the blood flow but also indirectly increases the muscle oxygenation.

Similarly, the previous study which tested 63 uninjured subjects' forearms,

shows that the muscle oxygenation baseline will not significantly change by measuring at different times (Cole, 2011).

The results reject hypothesis 3a, the acute KT application did not increase the VL or VM sitting baseline. The paired t-test states that the VM difference between D3 and D2 is not large enough to show the statistical significance ($p=0.062$), even though the sitting baseline in VM raw data grouping shows that the treatment leg only has two situations, (a) sitting baseline increase (b) sitting baseline decrease with control leg as well, and OR is equal to 6. The control leg results in the VM muscle shows that D3 compared to D2 is a statistically insignificant increase ($p=0.825$, mean difference=-1.14), which also gives evidence that the sitting baseline might decrease if the treatment leg has no KT application. The follow-up study needs to increase the number of subjects to show the truth.

The effect of acute KT application in VL sitting baseline has an OR greater than 1 (OR=2.133) which indicates that the acute KT application is associated with VL sitting baseline increasing. Nevertheless, although the paired t-test shows that VL sitting baseline is statistically significantly increased ($p=0.045$) by the acute KT application, it could be a false positive because the Power shows only a 64.2% chance that the increase in TTF could be explained by acute KT application. Nevertheless, the control leg result can be examined to show if the trends in the two legs' sitting baseline are similar. The result in the control leg VM presents that no statistically significant increase was found in sitting baseline ($p=0.198$). The follow-up study needs to include more subjects to show if the increase is truly positive. As a result, both VM and VL show that the acute KT application could be associated with increasing sitting baseline, but more subjects are needed to support the statement.

Hypothesis 3b was rejected by the VM and VL results. According to the VM results, the sitting baseline in some of the subjects decreased more by extending the KT application duration. The VM sitting baseline RR and paired t-test results explained that a longer duration of KT application will decrease the sitting baseline. Two possible reasons could be made, (a) the KT has a decreasing effect in VM muscle sitting baseline, (b) KT had an effect in acute KT application, but the effectiveness decreased with the duration of KT application.

VL and VM have similar results, but the RR in VL is always greater than 1. However, when the KT application is extended, less association was seen between KT and sitting baseline increases. Moreover, the paired t-test results suggest that the duration of KT application is not a factor in increasing the VL sitting baseline.

The hypothesis 3c was rejected by the D7 comparisons. The residual effect can be defined in two ways, (a) the sitting baseline still increases after KT is removed, and (b) the sitting baseline on D7 is close to the value with KT application. In both VM and VL the results indicate that D7 did not statistically significantly increase in sitting baseline when compare to D6, which suggests that the residual effect (a) is invalid. When D7 is compared to D2, both VM and VL results indicate no statistically significant increase in sitting baseline after KT removal. As a result, the residual definition (b) is abandoned as well, and no residual effect in rSO₂ sitting baseline was suggested.

4.2.2 Minimum rSO₂ level:

The literature review in this study did not find any previous research that discussed the minimum rSO₂ variable. Moreover, no reference can be considered to show how the minimum rSO₂ levels change after using KT. Therefore, a two-sided

test was chosen to investigate the change of minimum rSO₂.

In the VM muscle, hypothesis 4a failed to reject, due to the minimum rSO₂ levels' statistically significant change after the acute KT application ($p=0.022$, Power=80.7%). Not only that, to prove that the effect from acute KT application is true, the control leg was tested as well. The control leg result on D3 compared to D2 shows the minimum rSO₂ in VM is statistically insignificantly different ($p=0.969$, mean difference=0.0006). The mean difference in the treatment leg is equal to 0.0663, which determines that the acute KT increases the minimum rSO₂ in the VM. Moreover, the raw data also suggests that more than 69% of subjects have increased the minimum rSO₂ levels in the treatment leg VM when comparing D3 to D2. The reason for minimum rSO₂ increasing could be attributed to the manufacturers claim that the blood flow and muscle oxygen will be increased by KT.

The VL muscle rejects hypothesis 3a because the difference between D3 and D2 is not large enough. According to the raw data, even though 10 subjects increased the minimum rSO₂ value on D3, the increase in the minimum rSO₂ levels cannot support that the difference truly exists.

Both VM and VL suggest that the duration of KT application will not affect the minimum rSO₂. The results reject hypothesis 4b, because 24, 48, and 72 hours of KT application have no statistically significant changes when compared to D3.

Hypothesis 4c was rejected because VM and VL have no evidence to support the definition (a) and (b) for residual effects. However, according to the raw data grouping, D7 to D6 in the VM shows that 9 subjects' treatment leg minimum rSO₂ levels decreased (69%). Yet, when D7 is compared to D2, 50% of subjects' treatment leg minimum rSO₂ increased, and rest of the subjects decreased. On the

other hand, VL minimum rSO₂ raw data also shows 9 subjects' treatment leg minimum rSO₂ decreased. 8 subjects decreased in D7 compare to the D2 result, and it is rational that D7 compared to D6 and D2 have similar results, because no statistically significant differences were found in the VL muscle.

4.2.3 Time to minimum rSO₂ in the trial:

Based on the literature review in this study, none of the studies discuss the time to minimum rSO₂ variable. Also, no trend was found in the raw data, and the two-sided paired t-test was chosen to examine the differences. The influence in time to minimum rSO₂ in the trial is not related to KT. The acute KT application did not change the VM and VL time to minimum rSO₂ result, based on the D3 to D2 comparison which has no statistically significant changes. Therefore, hypothesis 5a was rejected. Secondly, the results of the duration of KT application in time to minimum rSO₂ in the VM and VL muscles also show no statistically significant change, hence hypothesis 5b was rejected. The duration of KT application results tell that after a longer KT application, more subjects will have different changes. However, the treatment leg did not provide any evidence that KT will delay the time to minimum rSO₂ or shift to an earlier time. Just as for the other hypothesis results, the residual effect was not found after KT was removed for 24 hours.

The reason for no change in time to minimum muscle oxygenation could be due to the fact that the time is related to the subject's isotonic exercise performance, and every subject utilized the muscles to execute the task in a different way. First of all, according to the TTF results, both legs' TTF are enhanced, but the calculation of time to minimum rSO₂ level in the trial is based on TTF and the time that minimum rSO₂ occurred. Therefore, when time to minimum rSO₂ as a percentage of TTF is

similar but TTF increased, the minimum rSO₂ time is postponed actually. As a result, the muscle oxygenation uptake duration and recovery start point are related to the exercise duration, and not necessarily independent.

Overall, every subject consumes the rSO₂ in the VM and VL muscle differently. Surprisingly, some of the subjects consume the rSO₂ differently between the control leg and treatment leg. But according to the 14 subjects' muscle oxygenation results, 3 main categories can be defined as below:

1. Some subjects will see a recovery during the isotonic flexion/extension exercise when it reaches to the minimum rSO₂. The VL muscle in some of the subjects has more oxygen uptake than the VM muscle during the isotonic flexion/extension exercise, and it also recovers more from the minimum rSO₂ levels (Figure 34).
2. The VL and VM muscles in some of the subjects will have the same trend which consumes and recovers the rSO₂ simultaneously during the trial (Figure 41).
3. Some of subjects always decrease until the end of the trial (Figure 42), hence the minimum rSO₂ will occur at 100% of TTF.




Figure 41: rSO₂ levels - D4 Subject 9 control Leg - an example of when VL and VM have similar rSO₂ consumption and trends. The time displayed in the graph is the respective end of that trial




Figure 42: rSO₂ levels - D4 Subject 12 treatment Leg - An example of when VM and VL rSO₂ levels decrease until the end of the trial. The time displayed in the graph is the respective end of that trial

4.3 Summary

The goal of this research was to quantify the changes in performance and muscle oxygenation from acute and prolong KT application. Overall, there was

no evidence found to support that KT enhances isotonic knee flexion/extension endurance performance. The results of the subjects from acute and prolonged KT application were distributed from increasing, no change, and decreasing in TTF and rate. Subjects who were observed to have increased their performance also had indications of a learning effect or placebo effect.

There were changes due to KT application among the muscle oxygenation variables. The minimum level of rSO₂ during exercise did increase due to acute KT application. This could be due to the tape stretching the skin away from the muscle allowing oxygenated blood to flow more readily (which is claimed by the manufacturer), and thus the rSO₂ level did not reduce as much. Besides the increase observed in minimum rSO₂, KT did not result in any performance or muscle oxygenation changes.

4.4 Study Limitations

There are several limitations to this study that should be acknowledged. First, the duration of the test is eight days, which may not be long enough if evaluating the effect of KT on injury recovery. Future studies can have a longer project schedule to get more subjects enrolled.

Secondly, muscle strength could be included as a factor in future studies. There is substantial literature that uses electromyography to evaluate muscle strength and discuss the difference with/without Kinesiology Tape (Y. Konishi, 2013; Y. Shah, 2017; W. Moalla, 2006; C.Y. Huang, 2011; K. MacGregor, 2005; J. H. van Dieën, 2007). However, no study examined muscle strength (EMG data) with isotonic exercise. The performance changes from using KT might be more clearly defined if the relationship between muscle strength and exercise performance was

studied.

Third, the KT was always put on subjects' dominant leg in this research, which blocked the KT influences on the dominant and non-dominant leg. Future studies could add the leg factor to the experiment. Additionally, only one brand and one type of KT was used in this study, which limits the generalization of the results to all KT.

And last but not the least, the NIRS sensors are all put on the quads in this research. However, if the future study could overcome the comfort issue which is affected by the sensor placement, leg and Biodex, assessing the hamstring muscles is another viewpoint to discuss.

Chapter 5 Conclusion

This study was the first of its kind to determine the effects of KT application on healthy subjects during a fatiguing isotonic knee flexion/extension exercise. The reason for this study was to evaluate the claims of performance enhancement. Performance variables off TTF and rate were evaluated along with muscle oxygenation of the VL and VM muscles. The results in this study were:

- Application of KT to the knee joint did not enhance TTF and rate performance in isotonic flexion/extension exercise.
- KT application did increase the VL sitting baseline.
- Acute application of the KT increase the VM minimum rSO₂ levels during exercise.
- Wearing KT increases the minimum rSO₂ levels during exercise.

This study did demonstrate that KT can cause changes in an individual muscle oxygenation levels through increasing their sitting baseline, and minimum level during exercise. Manufacturers make broad claims that KT can cause this changes, and this study supports this claim. However, manufacturers and athletes use this claim to support the notion that KT can also improve performance. No evidence was found in this study to support the notion of enhancing endurance performance during an isotonic knee flexion/extension exercise for this particular tape. Any increases could be due to a placebo effect or, also found in the current study, a learning effect. Further research should be completed in order to generalize these results across other tapes.

References

- Akbaş, E., Atay, A. O., & Yüksel, I. (2011). The effects of additional kinesio taping over exercise in the treatment of patellofemoral pain syndrome. *Acta Orthopaedica et Traumatologica Turcica*, 45(5), 335-341.
- Aktas, G., & Baltacı, G. (2011). Does kinesiotaping increase knee muscles strength and functional performance? *Isokinetics and Exercise Science*, 19(3), 149-155.
- Álvarez-Álvarez, S., San José, F., Rodríguez-Fernández, A., Güeita-Rodríguez, J., & Waller, B. (2014). Effects of Kinesio® Tape in low back muscle fatigue: randomized, controlled, doubled-blinded clinical trial on healthy subjects. *Journal of Back and Musculoskeletal Rehabilitation*, 27(2), 203-212.
- Aytar, A., Ozunlu, N., Surenkok, O., Baltacı, G., Oztop, P., & Karatas, M. (2011). Initial effects of kinesio® taping in patients with patellofemoral pain syndrome: A randomized, double-blind study. *Isokinetics and Exercise Science*, 19(2), 135-142.
- Bassett, K., Lingman, S., & Ellis, R. (2010). ML Roberts Prize Winner-The use and treatment efficacy of kinaesthetic taping for musculoskeletal conditions: A systematic review. *New Zealand Journal of Physiotherapy*, 38(2), 56.
- Bicici, S., Karatas, N., & Baltacı, G. (2012). Effect of athletic taping and kinesiotaping® on measurements of functional performance in basketball players with chronic inversion ankle sprains. *International Journal of Sports Physical Therapy*, 7(2), 154.
- Briem, K., Eythörsdóttir, H., Magnúsdóttir, R. G., Pálmarrsson, R., Rúnarsdóttir, T., & Sveinsson, T. (2011). Effects of kinesio tape compared with nonelastic sports tape and the untaped ankle during a sudden inversion perturbation in male athletes. *Journal of Orthopaedic & Sports Physical Therapy*, 41(5), 328-335.
- Burton, K. A., Clarke, R. D., McClune, T. D., & Tillotson, M. K. (1996). The natural history of low back pain in adolescents. *Spine*, 21(20), 2323-2328.
- Castro-Sánchez, A. M., Lara-Palomo, I. C., Matarán-Peñarrocha, G. A., Fernández-Sánchez, M., Sánchez-Labraca, N., & Arroyo-Morales, M. (2012). Kinesio Taping reduces disability and pain slightly in chronic non-specific low back pain: a randomised trial. *Journal of Physiotherapy*, 58(2), 89-95.

- Chang, H.-Y., Chou, K.-Y., Lin, J.-J., Lin, C.-F., & Wang, C.-H. (2010). Immediate effect of forearm Kinesio taping on maximal grip strength and force sense in healthy collegiate athletes. *Physical Therapy in Sport, 11*(4), 122-127.
- Chatfield, C. (2016). *The analysis of time series: an introduction*: CRC press.
- Cheng, A. J., & Rice, C. L. (2005). Fatigue and recovery of power and isometric torque following isotonic knee extensions. *Journal of Applied Physiology, 99*(4), 1446-1452.
- Chtourou, H., Driss, T., Souissi, S., Gam, A., Chaouachi, A., & Souissi, N. (2012). The effect of strength training at the same time of the day on the diurnal fluctuations of muscular anaerobic performances. *The Journal of Strength & Conditioning Research, 26*(1), 217-225.
- de Almeida Lins, C. A., Neto, F. L., de Amorim, A. B. C., de Brito Macedo, L., & Brasileiro, J. S. (2013). Kinesio Taping® does not alter neuromuscular performance of femoral quadriceps or lower limb function in healthy subjects: Randomized, blind, controlled, clinical trial. *Manual Therapy, 18*(1), 41-45.
- DeLorey, D. S., Shaw, C. N., Shoemaker, J. K., Kowalchuk, J. M., & Paterson, D. H. (2004). The effect of hypoxia on pulmonary O₂ uptake, leg blood flow and muscle deoxygenation during single- leg knee- extension exercise. *Experimental physiology, 89*(3), 293-302.
- Diracoglu, D., Aydin, R., Baskent, A., & Celik, A. (2005). Effects of kinesthesia and balance exercises in knee osteoarthritis. *JCR: Journal of Clinical Rheumatology, 11*(6), 303-310.
- Drouin, J. L., McAlpine, C. T., Primak, K. A., & Kissel, J. (2013). The effects of kinesiotape on athletic-based performance outcomes in healthy, active individuals: a literature synthesis. *The Journal of the Canadian Chiropractic Association, 57*(4), 356.
- Fahs, C. A., Loenneke, J. P., Thiebaud, R. S., Rossow, L. M., Kim, D., Abe, T., . . . Bembem, M. G. (2015). Muscular adaptations to fatiguing exercise with and without blood flow restriction. *Clinical Physiology and Functional Imaging, 35*(3), 167-176.
- Fayson, S. D., Needle, A. R., & Kaminski, T. W. (2013). The effects of ankle Kinesio® taping on ankle stiffness and dynamic balance. *Research in Sports Medicine, 21*(3), 204-216.

- Fu, T.-C., Wong, A. M., Pei, Y.-C., Wu, K. P., Chou, S.-W., & Lin, Y.-C. (2008). Effect of Kinesio taping on muscle strength in athletes—a pilot study. *Journal of Science and Medicine in Sport*, 11(2), 198-201.
- Gart, M. S., & Wiedrich, T. A. (2017). Therapy and Rehabilitation for Upper Extremity Injuries in Athletes. *Hand clinics*, 33(1), 207-220.
- González-Iglesias, J., Fernández-de-Las-Peñas, C., Cleland, J., Huijbregts, P., & Gutiérrez-Vega, M. D. R. (2009). Short-term effects of cervical kinesio taping on pain and cervical range of motion in patients with acute whiplash injury: a randomized clinical trial. *Journal of Orthopaedic & Sports Physical Therapy*, 39(7), 515-521.
- Gramatikova, M., Vesenkov, S., Popova, D., Mitova, S., & Mitova, E. (2016). Kinesiotherapy recovery of the strength endurance of m. quadriceps femoris after reconstruction of the acl. *Sport Science*, 9, 7.
- Halseth, T., McChesney, J. W., DeBeliso, M., Vaughn, R., & Lien, J. (2004). The effects of kinesio™ taping on proprioception at the ankle. *Journal of Sports Science & Medicine*, 3(1), 1.
- Han, J. T., & Lee, J.-h. (2014). Effects of kinesiology taping on repositioning error of the knee joint after quadriceps muscle fatigue. *Journal of Physical Therapy Science*, 26(6), 921-923.
- Hsu, Y.-H., Chen, W.-Y., Lin, H.-C., Wang, W. T., & Shih, Y.-F. (2009). The effects of taping on scapular kinematics and muscle performance in baseball players with shoulder impingement syndrome. *Journal of Electromyography and Kinesiology*, 19(6), 1092-1099.
- Huang, C.-Y., Hsieh, T.-H., Lu, S.-C., & Su, F.-C. (2011). Effect of the Kinesio tape to muscle activity and vertical jump performance in healthy inactive people. *Biomedical Engineering Online*, 10(1), 70.
- Hwang-Bo, G., & Lee, J.-H. (2011). Effects of kinesio taping in a physical therapist with acute low back pain due to patient handling: a case report. *International Journal of Occupational Medicine and Environmental Health*, 24(3), 320.
- Ibrahim, A. R., & Atya, A. M. (2015). Kinesio Taping versus sensorymotor training for patients with knee osteoarthritis. *International Journal of Therapies and Rehabilitation Research*, 4(3), 9-14.
- Iellamo, F., Legramante, J. M., Raimondi, G., Castrucci, F., Damiani, C., Foti, C., . . . Caruso, I. (1997). Effects of isokinetic, isotonic and isometric

- submaximal exercise on heart rate and blood pressure. *European Journal of Applied Physiology and Occupational Physiology*, 75(2), 89-96.
- Jackson, K., Simon, J. E., & Docherty, C. L. (2016). Extended use of kinesiology tape and balance in participants with chronic ankle instability. *Journal of Athletic Training*, 51(1), 16-21.
- Kase, K., Wallis, J., & Kase, T. (2003). Clinical therapeutic applications of the Kinesio taping method.: Ken Ikai Co Ltd: Tokyo.
- Kaya, E., Zinnuroglu, M., & Tugcu, I. (2011). Kinesio taping compared to physical therapy modalities for the treatment of shoulder impingement syndrome. *Clinical Rheumatology*, 30(2), 201-207.
- Knapman, H. J., Fallon, T., O'Connor, M., Titmus, L. A., Choy, S. T., Hornsby, C., . . . Shum, G. L. (2017). The effect of elastic therapeutic taping on lumbar extensor isokinetic performance. *Physical Therapy in Sport*, 25, 9-14.
- Konishi, Y. (2013). Tactile stimulation with Kinesiology tape alleviates muscle weakness attributable to attenuation of Ia afferents. *Journal of Science and Medicine in Sport*, 16(1), 45-48.
- Lee, J.-H., Yoo, W.-G., & Lee, K.-S. (2010). Effects of head-neck rotation and kinesio taping of the flexor muscles on dominant-hand grip strength. *Journal of Physical Therapy Science*, 22(3), 285-289.
- Lee, K. Y., Lee, S., Choi, A. R., Choi, C.-H., & Mun, J. H. (2011). Endurance time prediction of biceps brachii muscle using Dimitrov spectral index of surface electromyogram during isotonic contractions. *International Journal of Precision Engineering and Manufacturing*, 12(4), 711-717.
- Lee, M. H., Lee, C. R., Park, J. S., Lee, S. Y., Jeong, T. G., Son, G. S., . . . Kim, Y. K. (2011). Influence of kinesio taping on the motor neuron conduction velocity. *Journal of Physical Therapy Science*, 23(2), 313-315.
- Llopis, G., & Aranda, C. (2012). Physiotherapy intervention with kinesio taping in patients suffering chronic neck pain. A pilot study. *Fisioterapia*, 34(5), 189-195.
- Luque-Suarez, A., Gijon-Nogueron, G., Baron-Lopez, F. J., Labajos-Manzanares, M. T., Hush, J., & Hancock, M. J. (2014). Effects of kinesiotaping on foot posture in participants with pronated foot: a quasi-randomised, double-blind study. *Physiotherapy*, 100(1), 36-40.

- MacGregor, K., Gerlach, S., Mellor, R., & Hodges, P. W. (2005). Cutaneous stimulation from patella tape causes a differential increase in vasti muscle activity in people with patellofemoral pain. *Journal of Orthopaedic Research*, 23(2), 351-358.
- Maćkała, K., Michalski, R., & Ćoh, M. (2010). Asymmetry of step length in relationship to leg strength in 200 meters sprint of different performance levels. *Journal of Human Kinetics*, 25, 101-108.
- McCurdy, K., & Langford, G. (2005). Comparison of unilateral squat strength between the dominant and non-dominant leg in men and women. *Journal of Sports Science & Medicine*, 4(2), 153.
- Moalla, W., Merzouk, A., Costes, F., Tabka, Z., & Ahmaidi, S. (2006). Muscle oxygenation and EMG activity during isometric exercise in children. *Journal of Sports Sciences*, 24(11), 1195-1201.
- Montgomery, D. C., Jennings, C. L., & Kulahci, M. (2015). *Introduction to time series analysis and forecasting*: John Wiley & Sons.
- Nakajima, M. A., & Baldrige, C. (2013). The effect of kinesio® tape on vertical jump and dynamic postural control. *International Journal of Sports Physical Therapy*, 8(4), 393.
- Paoloni, M., Bernetti, A., Fratocchi, G., Mangone, M., Parrinello, L., Del Pilar Cooper, M., . . . Santilli, V. (2011). Kinesio Taping applied to lumbar muscles influences clinical and electromyographic characteristics in chronic low back pain patients. *Eur J Phys Rehabil Med*, 47(2), 237-244.
- Parreira, P. d. C. S., Costa, L. d. C. M., Junior, L. C. H., Lopes, A. D., & Costa, L. O. P. (2014). Current evidence does not support the use of Kinesio Taping in clinical practice: a systematic review. *Journal of Physiotherapy*, 60(1), 31-39.
- Perrine, J. J. (1969). Isokinetic exercise process and apparatus: Google Patents.
- Pliner, J., Principe, A. H., Loshek, P., & Campbell-Kyureghyan, N. (2015). *Can kinesiology tapes affect knee performance in healthy subjects?* Paper presented at the Biomedical Conference (GLBC), 2015 IEEE Great Lakes.
- Poon, K., Li, S., Roper, M., Wong, M., Wong, O., & Cheung, R. (2015). Kinesiology tape does not facilitate muscle performance: a deceptive controlled trial. *Manual Therapy*, 20(1), 130-133.

- Preece, H., & White, P. (2017). Does kinesiology tape increase trunk forward flexion? *Journal of Bodywork and Movement Therapies*, 21(3), 618-625.
- Principe, A. H., Johnson, B., & Campbell-Kyureghyan, N. (2014). Knee Strength and Muscle Oxygenation Changes due to Prolonged Kneeling. *Knee*.
- Ptak, A., Konieczny, G., & Stefańska, M. (2013). The influence of short-term kinesiology taping on force-velocity parameters of the rectus abdominis muscle. *Journal of Back and Musculoskeletal Rehabilitation*, 26(3), 291-297.
- Rahnama, N., Lees, A., & Bambaecichi, E. (2005). A comparison of muscle strength and flexibility between the preferred and non-preferred leg in English soccer players. *Ergonomics*, 48(11-14), 1568-1575.
- Ruggiero, S. A., Frost, L. R., Vallis, L. A., & Brown, S. H. (2016). Effect of short-term application of kinesio tape on the flexion-relaxation phenomenon, trunk postural control and trunk repositioning in healthy females. *Journal of Sports Sciences*, 34(9), 862-870.
- Saavedra-Hernández, M., Castro-Sánchez, A. M., Arroyo-Morales, M., Cleland, J. A., Lara-Palomo, I. C., & Fernandez-De-Las-Penas, C. (2012). Short-term effects of kinesio taping versus cervical thrust manipulation in patients with mechanical neck pain: a randomized clinical trial. *Journal of Orthopaedic & Sports Physical Therapy*, 42(8), 724-730.
- Sannicandro, I., Cofano, G., Rosa, R. A., & Piccinno, A. (2014). Balance training exercises decrease lower-limb strength asymmetry in young tennis players. *Journal of Sports Science & Medicine*, 13(2), 397.
- Scheeren, T., Schober, P., & Schwarte, L. (2012). Monitoring tissue oxygenation by near infrared spectroscopy (NIRS): background and current applications. *Journal of Clinical Monitoring and Computing*, 26(4), 279-287.
- Semple, S., Esterhuysen, C., & Grace, J. (2012). The effects of kinesio ankle taping on postural stability in semiprofessional rugby union players. *Journal of Physical Therapy Science*, 24(12), 1239-1242.
- Shah, Y., Arkesteijn, M., Thomas, D., Whyman, J., & Passfield, L. (2017). The acute effects of integrated myofascial techniques on lumbar paraspinal blood flow compared with kinesio-taping: A pilot study. *Journal of Bodywork and Movement Therapies*, 21(2), 459-467.

- Shields, C. A., Needle, A. R., Rose, W. C., Swanik, C. B., & Kaminski, T. W. (2013). Effect of elastic taping on postural control deficits in subjects with healthy ankles, copers, and individuals with functional ankle instability. *Foot & Ankle International*, *34*(10), 1427-1435.
- Simon, J., Garcia, W., & Docherty, C. L. (2014). The effect of kinesio tape on force sense in people with functional ankle instability. *Clinical Journal of Sport Medicine*, *24*(4), 289-294.
- Şimşek, H., Balki, S., Keklik, S. S., Öztürk, H., & Elden, H. (2013). Does Kinesio taping in addition to exercise therapy improve the outcomes in subacromial impingement syndrome? A randomized, double-blind, controlled clinical trial. *Acta Orthopaedica et Traumatologica Turcica*, *47*(2), 104-110.
- Słupik, A., Dwornik, M., Białoszewski, D., & Zych, E. (2007). Effect of Kinesio Taping on bioelectrical activity of vastus medialis muscle. Preliminary report. *Ortopedia, Traumatologia, Rehabilitacja*, *9*(6), 644-651.
- Soylu, A. R., Irmak, R., & Baltaci, G. (2011). Acute effects of kinesiotaping on muscular endurance and fatigue by using surface electromyography signals of masseter muscle. *Med Sport*, *15*(1), 13-16.
- Strutzenberger, G., Moore, J., Griffiths, H., Schwameder, H., & Irwin, G. (2016). Effects of gluteal kinesio-taping on performance with respect to fatigue in rugby players. *European Journal of Sport Science*, *16*(2), 165-171.
- Thelen, M. D., Dauber, J. A., & Stoneman, P. D. (2008). The clinical efficacy of kinesio tape for shoulder pain: a randomized, double-blinded, clinical trial. *Journal of Orthopaedic & Sports Physical Therapy*, *38*(7), 389-395.
- Tsai, C.-T., Chang, W.-D., & Lee, J.-P. (2010). Effects of short-term treatment with kinesiotaping for plantar fasciitis. *Journal of Musculoskeletal Pain*, *18*(1), 71-80.
- Tsai, H.-J., Hung, H.-C., Yang, J.-L., Huang, C.-S., & Tsauo, J.-Y. (2009). Could Kinesio tape replace the bandage in decongestive lymphatic therapy for breast-cancer-related lymphedema? A pilot study. *Supportive Care in Cancer*, *17*(11), 1353.
- Van der Harst, J., Gokeler, A., & Hof, A. (2007). Leg kinematics and kinetics in landing from a single-leg hop for distance. A comparison between dominant and non-dominant leg. *Clinical Biomechanics*, *22*(6), 674-680.
- van Dieën, J. H., Westebring-van der Putten, E. P., Kingma, I., & de Looze, M. P. (2009). Low-level activity of the trunk extensor muscles causes

electromyographic manifestations of fatigue in absence of decreased oxygenation. *Journal of Electromyography and Kinesiology*, 19(3), 398-406.

Vithoulka, I., Beneka, A., Malliou, P., Aggelousis, N., Karatsolis, K., & Diamantopoulos, K. (2010). The effects of Kinesio-Taping® on quadriceps strength during isokinetic exercise in healthy non athlete women. *Isokinetics and Exercise Science*, 18(1), 1-6.

Wilson, B., & Bialocerkowski, A. (2015). The Effects of Kinesiotape Applied to the Lateral Aspect of the Ankle: Relevance to Ankle Sprains—A Systematic Review. *PloS one*, 10(6), e0124214.

Wong, O. M., Cheung, R. T., & Li, R. C. (2012). Isokinetic knee function in healthy subjects with and without Kinesio taping. *Physical Therapy in Sport*, 13(4), 255-258.

Yao, F.-S. F., Tseng, C.-C. A., Ho, C.-Y. A., Levin, S. K., & Illner, P. (2004). Cerebral oxygen desaturation is associated with early postoperative neuropsychological dysfunction in patients undergoing cardiac surgery. *Journal of Cardiothoracic and Vascular Anesthesia*, 18(5), 552-558.

Yoshida, A., & Kahanov, L. (2007). The effect of kinesio taping on lower trunk range of motions. *Research in Sports Medicine*, 15(2), 103-112.

Zhang, S., Fu, W., Pan, J., Wang, L., Xia, R., & Liu, Y. (2016). Acute effects of Kinesio taping on muscle strength and fatigue in the forearm of tennis players. *Journal of Science and Medicine in Sport*, 19(6), 459-464.

APPENDICES

Appendix A: Isotonic Flexion/Extension Exercise TTF

Table A- 1: TTF during isotonic knee flexion/extension exercise from Day 2 to Day 8

96

| TTF (sec) | | | | | | | | | | | | | | |
|------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| | Day 2 | | Day 3 | | Day 4 | | Day 5 | | Day 6 | | Day 7 | | Day 8 | |
| | Left | Right | Left | Right | Left | Right | Left | Right | Left | Right | Left | Right | Left | Right |
| S1 | 82 | 93 | 78 | 79 | 86 | 92 | 111 | 118 | 131 | 116 | 122 | 155 | 95 | 89 |
| S2 | 39 | 39 | 40 | 39 | 36 | 41 | 48 | 46 | 45 | 49 | 45 | 49 | 51 | 62 |
| S3 | 95.5 | 103 | 126 | 167 | 105.5 | 159 | 139 | 188 | 108 | 218 | 116.5 | 234.5 | 133 | 244 |
| S4 | 114 | 181 | 135 | 217 | 107 | 270 | 144 | 182 | 191 | 211 | 209 | 316 | 258 | 255 |
| S5 | 63 | 65 | 70 | 71 | 97 | 92 | 72 | 79 | 91 | 82 | 75 | 79 | 88 | 92 |
| S6 | 160 | 70 | 93 | 94 | 75 | 70 | 81 | 91 | 92 | 123 | N/A | N/A | N/A | N/A |
| S7 | 292 | 293 | 286 | 282 | 297 | 324 | 369 | 375 | 387 | 441 | 475 | 467 | 390 | 420 |
| S8 | 46 | 45 | 49 | 51 | 58 | 56 | 60 | 59 | 64 | 65 | 67 | 66 | 75 | 72 |
| S9 | 36 | 42 | 41 | 45 | 48 | 51 | 52 | 59 | 52 | 44 | 47 | 49 | 51 | 49 |
| S10 | 23 | 25 | 11 | 26 | 28 | 21 | 32 | 31 | 28 | 17 | 30 | 30 | 30 | 23 |
| S11 | 34 | 35 | 35 | 33 | 40 | 40 | 42 | 32 | 32 | 30 | 37 | 35 | 43 | 35 |
| S12 | 47 | 50 | 37 | 48 | 25 | 19 | 19 | 20 | 24 | 23 | 21 | 23 | 22 | 27 |
| S13 | 52 | 53 | 58 | 43 | 58 | 57 | 61 | 57 | 60 | 57 | 68 | 86 | 83 | 74 |
| S14 | 60 | 69 | 53 | 67 | 52 | 47 | 45 | 48 | 38 | 38 | 38 | 50 | 46 | 51 |

Table A- 2: The distribution of changes in TTF for the treatment and control leg, which was used to calculate the OR based on the acute of KT application

| | | Treatment Leg | Control Leg |
|----------|-----------------|---------------|-------------|
| Exposure | Increase TTF | 7 | 8 |
| | No increase TTF | 7 | 6 |
| | | OR | 0.75 |

Table A- 3: Number of subjects with RR for TTF based on duration of KT application (D3 compare to D4 through D6)

| | D4-D3 | | D5-D3 | | D6-D3 | |
|---------------|---------------|-------------------|---------------|-------------------|---------------|-------------------|
| | TTF Increased | TTF Not increased | TTF Increased | TTF Not increased | TTF Increased | TTF Not increased |
| Treatment Leg | 9 | 5 | 9 | 5 | 8 | 6 |
| Control Leg | 7 | 7 | 11 | 3 | 9 | 5 |
| | RR | 1.286 | RR | 0.818 | RR | 0.89 |

Table A- 4: The statistic results for hypothesis 1 a (the acute KT application), 1b (duration of KT application), 1c (KT application residual effect).

| Hypothesis | Days between | Mean difference | Range difference | p-value | Power |
|---|--------------|-----------------|------------------|---------|---------|
| H1a. Acute of KT application | D3-D2 | -2 | 20 | 0.265 | 33.6% |
| H1b. Duration of KT application | D4-D3 | 5.5 | 82 | 0.235 | 20.5% |
| | D5-D3 | 7.5 | 40 | 0.063 | 53.0% |
| | D6-D3 | 10 | 80 | 0.139 | 29.4% |
| H1c. KT application residual effect | D7-D2 | 12 | 162 | 0.034* | 99.6%▲ |
| | D7-D6 | 8.5 | 42 | 0.005* | 92.5%▲ |
| H1c. D7 compare to D2 and D6 control leg results | D7-D2 | 12 | 37 | 0.005* | 100.0%▲ |
| | D7-D6 | 1 | 34 | 0.380 | 38.0% |

* indicates statistical significance between median TTF for each hypothesis comparison

▲ presents the Power is greater than 80%

Table A- 5: The coefficient β in time series shows the TTF trends from D2 to D8 for each subject and each leg.

| Subjects | Control Leg | Treatment Leg |
|------------------------|--------------------|----------------------|
| S1 | 6.14 | 5.86 |
| S2 | 1.964 | 3.464 |
| S3 | 3.43 | 22.04 |
| S4 | 23.71 | 12.89 |
| S5 | 2.82 | 3.11 |
| S6 | -14.8 | 10.3 |
| S7 | 27.21 | 31 |
| S8 | 4.607 | 4.286 |
| S9 | 2.179 | 0.79 |
| S10 | 2.11 | -0.07 |
| S11 | 0.821 | -0.214 |
| S12 | -3.86 | -4.11 |
| S13 | 4.107 | 5.32 |
| S14 | -3.071 | -3.46 |
| Mean Difference | 2.42 | |
| SD | 8.94 | |
| <i>p-value</i> | 0.165 | |

* indicates statistical significance between control leg TTF for each hypothesis comparison.

Appendix B: Isotonic Flexion/Extension Exercise Rate

Table B- 1: Rate during isotonic knee flexion/extension exercise from Day 2 to Day 8

96

| Rate (cycle/sec) | | | | | | | | | | | | | | |
|------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| | Day 2 | | Day 3 | | Day 4 | | Day 5 | | Day 6 | | Day 7 | | Day 8 | |
| | Left | Right | Left | Right | Left | Right | Left | Right | Left | Right | Left | Right | Left | Right |
| S1 | 0.476 | 0.505 | 0.551 | 0.544 | 0.500 | 0.533 | 0.495 | 0.517 | 0.519 | 0.517 | 0.541 | 0.529 | 0.579 | 0.663 |
| S2 | 0.974 | 0.974 | 1.000 | 0.974 | 0.972 | 0.951 | 0.979 | 1.000 | 0.956 | 0.959 | 0.956 | 0.959 | 0.941 | 0.935 |
| S3 | 0.775 | 0.835 | 0.651 | 0.856 | 0.853 | 0.890 | 0.820 | 0.872 | 0.833 | 0.856 | 0.850 | 0.896 | 0.812 | 0.881 |
| S4 | 0.807 | 1.061 | 0.759 | 0.742 | 0.822 | 0.781 | 0.813 | 0.753 | 0.835 | 0.777 | 0.787 | 0.802 | 0.773 | 0.694 |
| S5 | 0.857 | 0.792 | 0.807 | 0.845 | 0.825 | 0.772 | 0.826 | 0.810 | 0.835 | 0.817 | 0.840 | 0.861 | 0.847 | 0.793 |
| S6 | 0.581 | 0.700 | 0.618 | 0.633 | 0.633 | 0.671 | 0.623 | 0.610 | 0.582 | 0.598 | N/A | N/A | N/A | N/A |
| S7 | 0.808 | 0.812 | 0.839 | 0.819 | 0.862 | 0.840 | 0.846 | 0.891 | 0.881 | 0.862 | 0.851 | 0.925 | 0.892 | 0.886 |
| S8 | 0.804 | 0.800 | 0.857 | 0.843 | 0.845 | 0.839 | 0.867 | 0.915 | 0.844 | 0.877 | 0.896 | 0.864 | 0.867 | 0.875 |
| S9 | 0.833 | 0.762 | 0.780 | 0.733 | 0.833 | 0.745 | 0.788 | 0.695 | 0.769 | 0.818 | 0.894 | 0.816 | 0.941 | 0.939 |
| S10 | 0.870 | 0.800 | 0.636 | 0.885 | 0.786 | 0.952 | 0.813 | 0.968 | 0.893 | 1.000 | 0.833 | 1.000 | 0.967 | 1.087 |
| S11 | 0.941 | 0.800 | 0.943 | 0.879 | 0.925 | 0.875 | 0.905 | 0.938 | 1.125 | 0.967 | 0.919 | 0.914 | 0.907 | 0.914 |
| S12 | 0.957 | 0.960 | 1.000 | 0.958 | 1.000 | 1.211 | 1.211 | 1.300 | 1.208 | 1.261 | 1.238 | 1.174 | 1.182 | 1.185 |
| S13 | 0.865 | 0.981 | 0.828 | 1.047 | 0.879 | 0.965 | 0.902 | 0.982 | 0.867 | 0.947 | 0.912 | 0.884 | 0.843 | 0.892 |
| S14 | 0.900 | 0.768 | 0.868 | 0.940 | 0.846 | 0.894 | 1.022 | 1.000 | 1.132 | 0.947 | 0.947 | 1.020 | 0.957 | 0.980 |

Table B- 2: The distribution of changes in rate for the treatment and control leg which was used to calculate the OR based on the acute of KT application

| | | Treatment Leg | Control Leg |
|----------|--------------|---------------|-------------|
| Exposure | Increase | 9 | 7 |
| | Not increase | 5 | 7 |
| | | OR | 1.8 |

Table B- 3: Number of subjects with RR for rate based on duration of KT application (D3 compare to D4 through D6)

| | D4-D3 | | D5-D3 | | D6-D3 | |
|---------------|---------------|-------------------|---------------|-------------------|---------------|-------------------|
| | Rate Increase | Rate Not increase | Rate Increase | Rate Not increase | Rate Increase | Rate Not increase |
| Treatment Leg | 7 | 7 | 9 | 5 | 8 | 6 |
| Control Leg | 8 | 6 | 11 | 3 | 9 | 5 |
| | RR | 0.875 | RR | 0.818 | RR | 0.89 |

Table B- 4: The statistic results for hypothesis 2a (the acute KT application), 2b (duration of KT application), 2c (KT application residual effect).

| Hypothesis in rate | Days between | Mean difference | Range difference | p-value | Power |
|--|--------------|-----------------|------------------|---------|--------|
| H2a. Acute of KT application | D3-D2 | 0.039 | 0.239 | 0.027* | 66.9% |
| H2a. D3-D2 control leg results | D3-D2 | 0.034 | 0.091 | 0.110 | 37.5% |
| H2b. Duration of KT application | D4-D3 | -0.004 | 0.149 | 0.556 | 7.3% |
| | D5-D3 | 0.021 | 0.406 | 0.094 | 39.2% |
| | D6-D3 | 0.007 | 0.215 | 0.201 | 22.9% |
| H2c. Residual after KT application | D7-D2 | 0.064 | 0.311 | 0.015* | 88.0%▲ |
| | D7-D6 | 0 | 0.160 | 0.447 | 7.6% |
| H2c. D7 compare to D2 and D6 control leg results | D7-D2 | 0.044 | 0.127 | 0.033* | 63.4% |
| | D7-D6 | 0.016 | 0.184 | 0.270 | 24.5% |

* indicates statistical significance between median rate for each hypothesis comparison

▲ presents the Power is greater than 80%

Table B- 5: The coefficient β in time series shows the rate trends from D2 to D8 for each subject and each leg.

| Subjects | Control Leg | Treatment Leg |
|------------------------|--------------------|----------------------|
| S1 | 0.011 | 0.015 |
| S2 | -0.007 | -0.005 |
| S3 | 0.018 | 0.007 |
| S4 | -0.001 | -0.035 |
| S5 | 0.002 | 0.003 |
| S6 | 0.001 | -0.023 |
| S7 | 0.011 | 0.016 |
| S8 | 0.009 | 0.011 |
| S9 | 0.017 | 0.028 |
| S10 | 0.028 | 0.041 |
| S11 | 0.002 | 0.018 |
| S12 | 0.049 | 0.041 |
| S13 | 0.003 | -0.022 |
| S14 | 0.022 | 0.030 |
| Mean Difference | -0.003 | |
| SD | 0.015 | |
| <i>p-value</i> | <i>0.741</i> | |

* indicates statistical significance between control leg Rate for each hypothesis comparison.

Appendix C: Sitting Baseline in VM/VL Muscles rSO₂ Levels Before the Test

Table C- 1: The sitting Baseline rSO₂ levels for the. (a) control leg VM muscles (b) control leg VL muscles (c) treatment leg VM muscles (d) treatment leg VL muscles

(a)

| Raw data of sitting baseline % rSO ₂ levels in control leg VM (%) | | | | | | | | |
|--|--------|--------|--------|--------|--------|--------|--------|--------|
| VM | D1 | D2 | D3 | D4 | D5 | D6 | D7 | D8 |
| S1 | 58.00% | 68.00% | 65.33% | 64.00% | 69.00% | 65.00% | 67.00% | 81.00% |
| S2 | 61.00% | 51.33% | 56.67% | 57.33% | 53.50% | 59.00% | 58.33% | 55.33% |
| S3 | 77.00% | 71.00% | 66.00% | 66.00% | 68.00% | 72.33% | 68.00% | 67.00% |
| S4 | 66.00% | 70.00% | 67.00% | 65.50% | 66.00% | 64.00% | 62.00% | 69.67% |
| S5 | 47.00% | 63.00% | 58.67% | 57.67% | 61.00% | 60.00% | 64.00% | 61.00% |
| S6 | 65.00% | 64.00% | 66.00% | 54.00% | 55.33% | 60.33% | N/A | N/A |
| S7 | 63.00% | 66.00% | 62.33% | 63.00% | 63.33% | 63.00% | 63.33% | 66.00% |
| S8 | 62.67% | 61.50% | 62.00% | 60.33% | 60.00% | 55.00% | 56.00% | 57.00% |
| S9 | 51.33% | 56.00% | 60.00% | 60.00% | 54.67% | 63.67% | 57.00% | 57.33% |
| S10 | 39.00% | 35.00% | 31.33% | 44.00% | 45.00% | 36.67% | 36.33% | 21.33% |
| S11 | 60.00% | 66.00% | 65.00% | 66.00% | 67.00% | 66.00% | 61.00% | 65.00% |
| S12 | 57.67% | 56.50% | 50.00% | 60.00% | 53.00% | 50.67% | 58.00% | 52.00% |
| S13 | 59.67% | 56.50% | 62.00% | 65.67% | 66.33% | 67.33% | 59.50% | 64.67% |
| S14 | 54.33% | 58.67% | 52.67% | 56.67% | 52.67% | 64.00% | 61.00% | 61.00% |

(b)

| Raw data of sitting baseline % rSO ₂ levels in VL control leg (%) | | | | | | | | |
|--|--------|--------|--------|--------|--------|--------|--------|--------|
| | D1 | D2 | D3 | D4 | D5 | D6 | D7 | D8 |
| S1 | 64.00% | 67.33% | 67.00% | 65.00% | 63.50% | 67.50% | 70.00% | 83.33% |
| S2 | 64.33% | 55.33% | 62.00% | 62.00% | 57.50% | 59.67% | 59.67% | 61.33% |
| S3 | 73.50% | 66.00% | 65.00% | 64.00% | 68.67% | 72.33% | 69.00% | 71.00% |
| S4 | 71.50% | 71.00% | 70.00% | 70.00% | 71.00% | 70.67% | 67.67% | 71.67% |
| S5 | 44.00% | 67.67% | 62.00% | 58.33% | 57.33% | 62.50% | 64.00% | 60.67% |
| S6 | 62.50% | 63.00% | 66.33% | 63.50% | 56.33% | 63.33% | N/A | N/A |
| S7 | 70.33% | 68.00% | 70.67% | 66.00% | 69.33% | 67.00% | 68.00% | 71.00% |
| S8 | 65.00% | 61.00% | 64.67% | 63.33% | 65.00% | 59.33% | 63.67% | 59.00% |
| S9 | 57.00% | 57.00% | 63.67% | 60.67% | 57.00% | 62.00% | 56.00% | 57.00% |
| S10 | 55.33% | 52.00% | 49.67% | 58.00% | 58.00% | 51.00% | 52.00% | 48.00% |
| S11 | 65.67% | 67.00% | 67.00% | 72.00% | 68.75% | 69.50% | 62.67% | 69.00% |
| S12 | 56.67% | 54.00% | 50.67% | 57.00% | 56.33% | 50.67% | 57.50% | 45.00% |
| S13 | 65.33% | 62.00% | 67.00% | 69.00% | 69.67% | 67.00% | 66.50% | 66.67% |
| S14 | 60.33% | 63.33% | 56.67% | 57.67% | 55.33% | 64.00% | 58.00% | 65.00% |

(c)

| Raw data of sitting baseline % rSO ₂ levels in VM treatment leg (%) | | | | | | | | |
|--|--------|--------|--------|--------|--------|--------|--------|--------|
| VM | D1 | D2 | D3 | D4 | D5 | D6 | D7 | D8 |
| S1 | 59.00% | 63.33% | 61.00% | 63.00% | 56.67% | 59.00% | 63.50% | 74.00% |
| S2 | 59.33% | 50.50% | 57.00% | 59.00% | 62.67% | 61.00% | 61.33% | 60.50% |
| S3 | 78.00% | 73.33% | 80.00% | 78.67% | 69.00% | 77.67% | 70.00% | 73.00% |
| S4 | 66.33% | 64.00% | 66.00% | 61.00% | 63.00% | 72.00% | 70.00% | 68.00% |
| S5 | 53.67% | 63.00% | 63.67% | 70.00% | 73.00% | 63.00% | 64.33% | 70.00% |
| S6 | 61.67% | 62.50% | 66.00% | 62.00% | 59.33% | 65.33% | N/A | N/A |
| S7 | 61.00% | 57.00% | 64.00% | 53.00% | 62.00% | 61.00% | 65.00% | 58.33% |
| S8 | 64.00% | 63.00% | 66.00% | 66.33% | 62.00% | 61.00% | 61.00% | 68.00% |
| S9 | 50.67% | 61.00% | 63.33% | 58.00% | 56.00% | 57.00% | 59.00% | 58.00% |
| S10 | 52.00% | 45.33% | 45.67% | 46.00% | 48.67% | 47.33% | 43.00% | 50.00% |
| S11 | 57.67% | 64.00% | 64.00% | 56.00% | 57.00% | 62.00% | 57.67% | 63.00% |
| S12 | 59.67% | 59.33% | 55.67% | 61.00% | 51.33% | 56.00% | 44.67% | 47.67% |
| S13 | 60.00% | 60.00% | 73.00% | 68.00% | 79.50% | 73.00% | 58.33% | 68.00% |
| S14 | 62.33% | N/A | 62.33% | 61.33% | 59.25% | 61.00% | 61.00% | 59.33% |

(d)

| Raw data of sitting baseline % rSO ₂ levels in VL treatment leg (%) | | | | | | | | |
|--|--------|--------|--------|--------|--------|--------|--------|--------|
| | D1 | D2 | D3 | D4 | D5 | D6 | D7 | D8 |
| S1 | 64.67% | 67.00% | 65.00% | 65.50% | 65.00% | 60.33% | 67.50% | 81.50% |
| S2 | 55.67% | 49.50% | 51.67% | 55.00% | 59.33% | 57.67% | 58.00% | 55.50% |
| S3 | 74.00% | 71.33% | 72.33% | 74.67% | 68.00% | 75.67% | 73.00% | 69.67% |
| S4 | 70.33% | 65.33% | 66.00% | 68.00% | 69.00% | 74.00% | 69.67% | 71.33% |
| S5 | 59.33% | 53.00% | 62.33% | 63.00% | 62.67% | 57.50% | 54.67% | 61.00% |
| S6 | 58.33% | 58.00% | 61.00% | 66.00% | 56.00% | 62.00% | N/A | N/A |
| S7 | 70.00% | 63.00% | 66.67% | 58.67% | 68.67% | 67.00% | 68.00% | 63.33% |
| S8 | 66.33% | 66.00% | 66.00% | 65.33% | 67.00% | 64.00% | 65.50% | 69.67% |
| S9 | 54.67% | 57.00% | 61.00% | 57.67% | 56.00% | 59.00% | 56.33% | 59.33% |
| S10 | 55.67% | 52.00% | 51.00% | 53.50% | 55.00% | 55.33% | 56.67% | 60.33% |
| S11 | 65.67% | 69.00% | 67.00% | 70.00% | 68.00% | 67.00% | 63.67% | 67.00% |
| S12 | 56.33% | 53.33% | 53.00% | 59.00% | 54.00% | 54.00% | 48.00% | 52.67% |
| S13 | 67.33% | 64.00% | 67.00% | 64.67% | 72.00% | 69.00% | 65.33% | 68.00% |
| S14 | 61.00% | N/A | 63.67% | 53.00% | 56.75% | 58.00% | 62.00% | 62.00% |

Table C- 2: The distribution of changes in muscle oxygenation sitting baseline for the treatment and control leg which was used to calculate the OR based on the acute of KT application. (a) VM muscles. (b) VL muscles

| (a) VM muscles | | Treatment Leg | Control Leg |
|------------------|--------------|---------------|-------------|
| Exposure Outcome | Increase | 10 | 5 |
| | Not increase | 3 | 9 |
| | | OR | 6 |

| (b) VL muscles | | Treatment Leg | Control Leg |
|------------------|--------------|---------------|-------------|
| Exposure Outcome | Increase | 8 | 6 |
| | Not increase | 5 | 8 |
| | | OR | 2.133 |

Table C- 3: Number of subjects with RR for muscle oxygenation sitting based on duration of KT application (D3 compare to D4 through D6). (a) VM muscles (b) VL muscles

| (a) VM muscles | D4-D3 | | D5-D3 | | D6-D3 | |
|----------------|----------|--------------|----------|--------------|----------|--------------|
| | Increase | Not increase | Increase | Not increase | Increase | Not increase |
| Treatment Leg | 6 | 8 | 3 | 11 | 4 | 10 |
| Control Leg | 7 | 7 | 9 | 5 | 10 | 4 |
| | RR | 0.857 | RR | 0.333 | RR | 0.4 |

| (b) VL muscles | D4-D3 | | D5-D3 | | D6-D3 | |
|----------------|----------|--------------|----------|--------------|----------|--------------|
| | Increase | Not increase | Increase | Not increase | Increase | Not increase |
| Treatment Leg | 9 | 5 | 9 | 5 | 8 | 6 |
| Control Leg | 5 | 9 | 7 | 7 | 7 | 7 |
| | RR | 1.8 | RR | 1.286 | RR | 1.14 |

Table C- 4: The statistic results for hypothesis 3a (the acute KT application), 3b (duration of KT application), 3c (KT application residual effect). (a) VM muscles. (b) VL muscles

(a) VM muscles

| Hypothesis | Day between | Mean difference | S.D. difference | <i>p-value</i> | Power |
|---|-------------|-----------------|-----------------|----------------|--------|
| H3a. Acute of KT application | D3-D2 | 2.55 | 4.75 | 0.062 | 60.2% |
| H3b. Duration of KT application | D4-D3 | -1.94 | 5.32 | 0.884 | 36.3% |
| | D5-D3 | -3.61 | 3.73 | 0.993 | 96.3%▲ |
| | D6-D3 | -0.97 | 3.56 | 0.806 | 24.9% |
| H3c. Residual after KT application | D7-D2 | 0.44 | 4.65 | 0.399 | 10.0% |
| | D7-D6 | 0.648 | 2.764 | 0.251 | 20.8% |

* indicates statistical significance between mean muscle oxygenation sitting baseline for each hypothesis comparison

▲ presents the Power is greater than 80%

(b) VL muscles

| Hypothesis | Day between | Mean difference | S.D. difference | <i>p-value</i> | Power |
|---|-------------|-----------------|-----------------|----------------|-------|
| H3a. Acute of KT application | D3-D2 | 1.849 | 3.264 | 0.045* | 0.642 |
| H3b. Duration of KT application | D4-D3 | -0.46 | 4.98 | 0.622 | 0.094 |
| | D5-D3 | -0.66 | 3.72 | 0.724 | 0.155 |
| | D6-D3 | -0.29 | 3.88 | 0.600 | 0.084 |
| H3c. Residual after KT application | D7-D2 | 1.32 | 4.07 | 0.143 | 0.311 |
| | D7-D6 | -0.78 | 3.72 | 0.768 | 0.184 |

* indicates statistical significance between mean muscle oxygenation sitting baseline for each hypothesis comparison

▲ presents the Power is greater than 80%

Appendix D: Minimum rSO₂ Levels in VM/VL Muscle During the

Task

Table D- 1: The minimum rSO₂ levels in the trial for the (a) control leg VM muscles (b) control leg VL muscles (c) treatment leg VM muscles (d) treatment leg VL muscles

(a)

| Minimum rSO ₂ levels in treatment leg VM during the task (% change with sitting baseline) | | | | | | | |
|--|--------|--------|--------|--------|--------|--------|--------|
| | D2 | D3 | D4 | D5 | D6 | D7 | D8 |
| S1 | 52.38% | 51.52% | 31.75% | 33.87% | 38.81% | 36.92% | 35.90% |
| S2 | 60.78% | 80.36% | 88.33% | 79.31% | 80.95% | 68.25% | 57.89% |
| S3 | 81.58% | 80.25% | 78.67% | 77.14% | 79.49% | 83.82% | 78.95% |
| S4 | 62.69% | 72.86% | 83.05% | 84.13% | 82.35% | 61.84% | 67.69% |
| S5 | 73.33% | 85.48% | 85.71% | 87.67% | 90.77% | 80.00% | 76.39% |
| S6 | 88.89% | 96.77% | 90.57% | 96.23% | 95.08% | N/A | N/A |
| S7 | 70.49% | 86.15% | 83.05% | 87.50% | 77.05% | 84.51% | 89.23% |
| S8 | 81.36% | 90.77% | 92.54% | 93.22% | 86.21% | 81.25% | 89.23% |
| S9 | 76.47% | 83.58% | 79.03% | 85.71% | 85.71% | 77.05% | 81.67% |
| S10 | 97.92% | 90.20% | 94.12% | 90.38% | 97.30% | 88.24% | 93.88% |
| S11 | 89.06% | 89.23% | 93.10% | 89.06% | 89.23% | 90.00% | 89.06% |
| S12 | 40.91% | 50.79% | 26.98% | 25.37% | 33.90% | 31.15% | 27.59% |
| S13 | 77.59% | 77.46% | 73.53% | 77.92% | 78.57% | 77.42% | 76.47% |
| S14 | N/A | 67.61% | 76.56% | 58.82% | 64.06% | 75.00% | 70.97% |

(b)

| Minimum rSO ₂ levels in treatment leg VL during the task (% change with sitting baseline) | | | | | | | |
|--|--------|--------|--------|--------|--------|--------|--------|
| | D2 | D3 | D4 | D5 | D6 | D7 | D8 |
| S1 | 50.00% | 51.52% | 34.85% | 38.81% | 44.78% | 39.06% | 41.46% |
| S2 | 51.85% | 41.38% | 46.30% | 40.74% | 63.79% | 50.85% | 58.18% |
| S3 | 46.97% | 56.25% | 53.85% | 58.44% | 56.58% | 43.48% | 50.65% |
| S4 | 33.82% | 36.59% | 19.70% | 32.84% | 40.54% | 39.51% | 34.33% |
| S5 | 9.59% | 25.37% | 32.89% | 27.14% | 43.28% | 25.68% | 50.00% |
| S6 | 53.23% | 59.70% | 52.31% | 56.45% | 65.15% | N/A | N/A |
| S7 | 32.86% | 31.43% | 23.44% | 35.71% | 31.34% | 55.07% | 58.33% |
| S8 | 49.28% | 64.18% | 62.86% | 55.07% | 59.09% | 46.97% | 43.28% |
| S9 | 55.71% | 59.72% | 55.07% | 60.34% | 51.61% | 55.74% | 57.97% |
| S10 | 92.59% | 96.30% | 89.47% | 94.44% | 91.67% | 89.83% | 89.83% |
| S11 | 33.80% | 50.00% | 42.86% | 42.31% | 45.07% | 32.31% | 25.40% |
| S12 | 6.45% | 12.90% | 7.35% | 4.35% | 20.34% | 0.00% | 1.72% |
| S13 | 77.94% | 61.76% | 67.16% | 70.83% | 69.01% | 67.61% | 75.71% |
| S14 | N/A | 10.77% | 30.36% | 18.46% | 0.00% | 10.00% | 37.93% |

(c)

| Minimum rSO ₂ levels in control leg VM during the task (% change with sitting baseline) | | | | | | | |
|--|--------|---------|---------|--------|--------|--------|---------|
| | D2 | D3 | D4 | D5 | D6 | D7 | D8 |
| S1 | 50.00% | 46.38% | 52.17% | 57.35% | 52.17% | 52.94% | 51.25% |
| S2 | 62.00% | 60.71% | 56.14% | 49.06% | 68.52% | 53.45% | 39.13% |
| S3 | 84.93% | 78.38% | 85.07% | 80.30% | 85.48% | 80.26% | 81.33% |
| S4 | 64.29% | 67.14% | N/A | 55.22% | 65.15% | 65.57% | 63.77% |
| S5 | 68.75% | 69.70% | 72.73% | 70.59% | 73.44% | 79.03% | 76.12% |
| S6 | 80.33% | 83.33% | 80.00% | 82.54% | 84.62% | N/A | N/A |
| S7 | 67.69% | 74.63% | 69.84% | 75.36% | 79.37% | 73.53% | 94.03% |
| S8 | 95.16% | 93.75% | 90.16% | 88.52% | 90.38% | 87.93% | 92.98% |
| S9 | 83.33% | 88.52% | 85.71% | 87.27% | 85.48% | 86.67% | 91.53% |
| S10 | 97.56% | 100.00% | 100.00% | 97.83% | 97.50% | 97.67% | 100.00% |
| S11 | 76.12% | 80.88% | 81.54% | 75.36% | 76.06% | 80.33% | 79.10% |
| S12 | 48.39% | 24.56% | 51.61% | 21.74% | 50.88% | 41.38% | 24.14% |
| S13 | 83.33% | 82.46% | 79.10% | 77.61% | 82.09% | 79.31% | 78.57% |
| S14 | 68.75% | 57.14% | 61.90% | 53.23% | 53.33% | 64.06% | 60.32% |

(d)

| Minimum rSO ₂ levels in control leg VL during the task (% change with sitting baseline) | | | | | | | |
|--|--------|--------|--------|--------|--------|--------|--------|
| | D2 | D3 | D4 | D5 | D6 | D7 | D8 |
| S1 | 13.85% | 33.33% | 50.70% | 20.97% | 40.30% | 40.91% | 38.75% |
| S2 | 61.02% | 60.00% | 70.97% | 63.16% | 72.13% | 70.49% | 57.14% |
| S3 | 59.15% | 43.42% | 42.42% | 63.77% | 48.57% | 36.71% | 53.16% |
| S4 | 28.95% | 46.75% | N/A | 41.03% | 44.59% | 38.24% | 38.67% |
| S5 | 36.92% | 21.13% | 32.84% | 28.36% | 33.33% | 40.58% | 35.82% |
| S6 | 36.21% | 46.03% | 22.58% | 31.75% | 50.00% | N/A | N/A |
| S7 | 64.79% | 72.97% | 48.48% | 57.33% | 55.56% | 64.29% | 86.30% |
| S8 | 33.82% | 52.17% | 38.81% | 57.58% | 63.79% | 62.50% | 26.79% |
| S9 | 77.78% | 79.37% | 75.76% | 75.00% | 83.33% | 84.21% | 84.48% |
| S10 | 91.23% | 98.11% | 93.10% | 91.38% | 96.08% | 96.23% | 96.08% |
| S11 | 34.78% | 44.29% | 40.54% | 32.47% | 33.77% | 44.44% | 13.89% |
| S12 | 15.63% | 3.57% | 14.75% | 8.62% | 5.66% | 25.00% | 1.89% |
| S13 | 88.14% | 81.82% | 87.14% | 80.28% | 85.07% | 85.07% | 81.54% |
| S14 | 37.10% | 37.50% | 33.87% | 28.57% | 34.92% | 0.00% | 33.85% |

Table D- 2: The statistic results for hypothesis 4a (the acute KT application), b (duration of KT application), c (KT application residual effect). (a) VM muscles. (b) VL muscles

(a) VM muscles

| Hypothesis | Day between | Mean difference | S.D. difference | p-value | Power |
|------------------------------------|-------------|-----------------|-----------------|---------|--------|
| H4a. Acute of KT application | D3-D2 | 0.066 | 0.081 | 0.022* | 80.7%▲ |
| H4a. D3-D2 control leg results | D3-D2 | 0.001 | 0.051 | 0.967 | 5.4% |
| H4b. Duration of KT application | D4-D3 | 0.015 | 0.056 | 0.384 | 14.9% |
| | D5-D3 | 0.014 | 0.037 | 0.241 | 25.7% |
| | D6-D3 | 0.005 | 0.052 | 0.741 | 06.3% |
| H4c. Residual after KT application | D7-D2 | 0.021 | 0.063 | 0.314 | 21.5% |
| | D7-D6 | -0.040 | 0.095 | 0.189 | 31.4% |

* indicates statistical significance between mean minimum rSO₂ levels in the trial for each hypothesis comparison

▲ presents the Power is greater than 80%

(b) VL muscles

| Hypothesis | Day between | Mean difference | S.D. difference | p-value | Power |
|------------------------------------|-------------|-----------------|-----------------|---------|-------|
| H4a. Acute of KT application | D3-D2 | 0.041 | 0.100 | 0.182 | 42.6% |
| H4b. Duration of KT application | D4-D3 | -0.028 | 0.097 | 0.297 | 17.2% |
| | D5-D3 | -0.016 | 0.064 | 0.379 | 13.5% |
| | D6-D3 | 0.020 | 0.094 | 0.321 | 16.9% |
| H4c. Residual after KT application | D7-D2 | 0.007 | 0.103 | 0.820 | 5.7% |
| | D7-D6 | -0.063 | 0.125 | 0.125 | 41.7% |

* indicates statistical significance between mean minimum rSO₂ levels in the trial for each hypothesis comparison

▲ presents the Power is greater than 80%

Appendix E: Time to Minimum rSO₂ Levels During the Trial

Table E- 1: The minimum rSO₂ levels' in the trial for the (a) control leg VM muscles (b) control leg VL muscles (c) treatment leg VM muscles (d) treatment leg VL muscles

(a)

| Time to minimum rSO ₂ levels in control leg VM (% of TTF) | | | | | | | |
|--|--------|---------|---------|--------|---------|---------|--------|
| | D2 | D3 | D4 | D5 | D6 | D7 | D8C |
| S1 | 95.46% | 86.36% | 37.93% | 55.17% | 51.43% | 60.61% | 29.03% |
| S2 | 63.64% | 58.33% | 63.64% | 46.67% | 50.00% | 61.54% | 40.00% |
| S3 | 23.08% | 15.15% | 21.43% | 81.08% | 21.43% | 19.35% | 17.14% |
| S4 | 23.33% | 17.14% | N/A | 18.92% | 12.24% | 11.32% | 10.45% |
| S5 | 29.41% | 38.89% | 24.00% | 52.63% | 33.33% | 95.00% | 33.33% |
| S6 | 15.00% | 32.00% | 40.00% | 50.00% | 68.00% | N/A | N/A |
| S7 | 34.21% | 60.27% | 49.33% | 40.86% | 39.80% | 52.50% | 6.06% |
| S8 | 38.46% | 42.86% | 37.50% | 35.29% | 29.41% | 27.78% | 25.00% |
| S9 | 70.00% | 58.33% | 50.00% | 42.86% | 53.33% | 38.46% | 50.00% |
| S10 | 57.14% | 25.00% | 12.50% | 66.67% | 100.00% | 55.56% | 11.11% |
| S11 | 60.00% | 90.00% | 58.33% | 50.00% | 54.55% | 81.82% | 50.00% |
| S12 | 53.85% | 54.55% | 100.00% | 83.33% | 100.00% | 100.00% | 85.71% |
| S13 | 60.00% | 100.00% | 93.33% | 94.12% | 64.71% | 50.00% | 68.18% |
| S14 | 37.50% | 35.71% | 40.00% | 38.46% | 58.33% | 40.00% | 30.77% |

(b)

| Time to minimum rSO ₂ levels in control leg VL (% of TTF) | | | | | | | |
|--|---------|---------|---------|--------|--------|--------|---------|
| | D2 | D3 | D4 | D5 | D6 | D7 | D8C |
| S1 | 100.00% | 86.36% | 41.38% | 58.62% | 28.57% | 69.70% | 25.81% |
| S2 | 100.00% | 58.33% | 100.00% | 53.33% | 58.33% | 53.85% | 53.33% |
| S3 | 23.08% | 18.18% | 35.71% | 13.51% | 21.43% | 19.35% | 17.14% |
| S4 | 23.33% | 14.29% | N/A | 18.92% | 12.24% | 11.32% | 10.45% |
| S5 | 35.29% | 38.89% | 24.00% | 52.63% | 33.33% | 50.00% | 33.33% |
| S6 | 20.00% | 28.00% | 40.00% | 31.82% | 36.00% | N/A | N/A |
| S7 | 10.53% | 16.44% | 68.00% | 81.72% | 51.02% | 48.33% | 13.13% |
| S8 | 46.15% | 50.00% | 37.50% | 41.18% | 29.41% | 27.78% | 25.00% |
| S9 | 70.00% | 58.33% | 42.86% | 50.00% | 53.33% | 38.46% | 42.86% |
| S10 | 71.43% | 100.00% | 62.50% | 66.67% | 37.50% | 66.67% | 33.33% |
| S11 | 60.00% | 60.00% | 50.00% | 50.00% | 54.55% | 54.55% | 41.67% |
| S12 | 53.85% | 54.55% | 87.50% | 83.33% | 85.71% | 85.71% | 100.00% |
| S13 | 40.00% | 37.50% | 33.33% | 35.29% | 35.29% | 33.33% | 31.82% |
| S14 | 37.50% | 35.71% | 53.33% | 38.46% | 41.67% | 60.00% | 30.77% |

(c)

| Time to minimum rSO ₂ levels in treatment leg VM (% of TTF) | | | | | | | |
|--|---------|---------|---------|---------|---------|---------|---------|
| | D2 | D3 | D4 | D5 | D6 | D7 | D8T |
| S1 | 44.000% | 100.00% | 90.00% | 28.13% | 83.33% | 90.00% | 96.15% |
| S2 | 63.636% | 54.55% | 50.00% | 42.86% | 46.15% | 46.67% | 29.41% |
| S3 | 77.778% | 86.05% | 90.24% | 82.00% | 96.43% | 86.67% | 91.94% |
| S4 | 13.043% | 16.36% | 14.49% | 14.89% | 14.81% | 88.75% | 9.23% |
| S5 | 38.889% | 47.37% | 25.00% | 28.57% | 22.73% | 42.86% | 58.33% |
| S6 | 26.316% | 24.00% | 36.84% | 32.00% | 15.15% | N/A | N/A |
| S7 | 69.333% | 27.78% | 47.56% | 38.95% | 50.89% | 37.29% | 26.42% |
| S8 | 38.462% | 35.71% | 31.25% | 31.25% | 100.00% | 100.00% | 100.00% |
| S9 | 50.000% | 50.00% | 42.86% | 37.50% | 50.00% | 50.00% | 46.15% |
| S10 | 71.429% | 100.00% | 85.71% | 77.78% | 100.00% | 77.78% | 71.43% |
| S11 | 40.000% | 44.44% | 45.45% | 55.56% | 55.56% | 50.00% | 50.00% |
| S12 | 92.857% | 78.57% | 100.00% | 100.00% | 100.00% | 100.00% | 75.00% |
| S13 | 80.000% | 83.33% | 93.75% | 81.25% | 93.75% | 34.78% | 100.00% |
| S14 | N/A | 20.00% | 41.67% | 30.77% | 36.36% | 21.43% | 21.43% |

(d)

| Time to minimum rSO ₂ levels in treatment leg VL (% of TTF) | | | | | | | |
|--|---------|---------|---------|---------|---------|---------|--------|
| | D2 | D3 | D4 | D5 | D6 | D7 | D8T |
| S1 | 32.00% | 100.00% | 53.33% | 28.13% | 36.67% | 30.00% | 61.54% |
| S2 | 63.64% | 100.00% | 100.00% | 100.00% | 69.23% | 100.00% | 58.82% |
| S3 | 25.93% | 13.95% | 14.63% | 14.00% | 98.21% | 10.00% | 91.94% |
| S4 | 13.04% | 10.91% | 8.70% | 12.77% | 12.96% | 7.50% | 10.77% |
| S5 | 38.89% | 31.58% | 50.00% | 38.10% | 36.36% | 66.67% | 29.17% |
| S6 | 31.58% | 28.00% | 36.84% | 32.00% | 24.24% | N/A | N/A |
| S7 | 81.33% | 43.06% | 32.93% | 88.42% | 52.68% | 24.58% | 15.09% |
| S8 | 38.46% | 57.14% | 37.50% | 37.50% | 27.78% | 33.33% | 30.00% |
| S9 | 58.33% | 66.67% | 50.00% | 43.75% | 58.33% | 50.00% | 46.15% |
| S10 | 85.71% | 71.43% | 85.71% | 55.56% | 100.00% | 55.56% | 71.43% |
| S11 | 60.00% | 77.78% | 72.73% | 66.67% | 66.67% | 70.00% | 60.00% |
| S12 | 50.00% | 64.29% | 100.00% | 85.71% | 100.00% | 57.14% | 62.50% |
| S13 | 100.00% | 41.67% | 37.50% | 43.75% | 87.50% | 100.00% | 40.00% |
| S14 | N/A | 30.00% | 33.33% | 38.46% | 54.55% | 35.71% | 35.71% |

Table E- 2: The statistic results for hypothesis 5a (the acute KT application), 5b (duration of KT application), 5c (KT application residual effect). (a) VM muscles. (b) VL muscles

(a) VM muscles

| Hypothesis | Day difference | Mean difference | S.D. difference | <i>p-value</i> | Power |
|---|----------------|-----------------|-----------------|----------------|-------|
| H5a. Acute of KT application | D3-D2 | 0.033 | 0.224 | <i>0.609</i> | 8.0% |
| H5b. Duration of KT application | D4-D3 | 0.019 | 0.138 | <i>0.613</i> | 7.7% |
| | D5-D3 | -0.062 | 0.227 | <i>0.326</i> | 15.7% |
| | D6-D3 | 0.069 | 0.217 | <i>0.253</i> | 19.9% |
| H5c. Residual after KT application | D7-D2 | 0.104 | 0.356 | <i>0.332</i> | 17.4% |
| | D7-D6 | -0.018 | 0.294 | <i>0.826</i> | 5.5% |

* indicates statistical significance between mean time to minimum rSO₂ levels in the trial for each hypothesis comparison

▲ presents the Power is greater than 80%

(b) VL muscles

| Hypothesis | Day difference | Mean difference | S.D. difference | <i>p-value</i> | Power |
|---|----------------|-----------------|-----------------|----------------|-------|
| H5a. Acute of KT application | D3-D2 | 0.021 | 0.318 | <i>0.814</i> | 5.6% |
| H5b. Duration of KT application | D4-D3 | -0.017 | 0.193 | <i>0.753</i> | 6.0% |
| | D5-D3 | -0.037 | 0.262 | <i>0.607</i> | 7.8% |
| | D6-D3 | 0.063 | 0.367 | <i>0.529</i> | 9.2% |
| H5c. Residual after KT application | D7-D2 | -0.036 | 0.245 | <i>0.626</i> | 7.9% |
| | D7-D6 | -0.123 | 0.329 | <i>0.201</i> | 25.6% |

* indicates statistical significance between mean time to minimum rSO₂ levels in the trial for each hypothesis comparison

▲ presents the Power is greater than 80%

Appendix F: rSO₂ Levels in VM/VL Muscle During the Isotonic Flexion/Extension Exercise




Figure F- 1: The rSO₂ levels in control leg VM and VL during isotonic exercise from D2 to D8 in Subject 1. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 2: The rSO₂ levels treatment leg VM and VL during isotonic exercise from D2 to D8 in Subject 1. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 3: The rSO₂ levels control leg VM and VL during isotonic exercise from D2 to D8 in Subject 2. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 4: The rSO₂ levels treatment leg VM and VL during isotonic exercise from D2 to D8 in Subject 2. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 5: The rSO₂ levels control leg VM and VL during isotonic exercise from D2 to D8 in Subject 3. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 6: The rSO₂ levels treatment leg VM and VL during isotonic exercise from D2 to D8 in Subject 3. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 7: The rSO₂ levels control leg VM and VL during isotonic exercise (no D4 data) in Subject 4. (a) D2 (b) D3 (c) D5 (d) D6 (e) D7 (f) D8. The time displayed in the graph is the respective end of that trial




Figure F- 8: The rSO₂ levels treatment leg VM and VL during isotonic exercise from D2 to D8 in Subject 4. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 9: The rSO₂ levels control leg VM and VL during isotonic exercise from D2 to D8 in Subject 5. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 10: The rSO₂ levels treatment leg VM and VL during isotonic exercise from D2 to D8 in Subject 5. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 11: The rSO₂ levels control leg VM and VL during isotonic exercise from D2 to D6 in Subject 6. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6. The time displayed in the graph is the respective end of that trial




Figure F- 12: The rSO₂ levels treatment leg VM and VL during isotonic exercise from D2 to D6 in Subject 6. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6. The time displayed in the graph is the respective end of that trial




Figure F- 13: The rSO₂ levels control leg VM and VL during isotonic exercise from D2 to D8 in Subject 7. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 14: The rSO₂ levels treatment leg VM and VL during isotonic exercise from D2 to D8 in Subject 7. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 15: The rSO₂ levels control leg VM and VL during isotonic exercise from D2 to D8 in Subject 8. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 16: The rSO₂ levels treatment leg VM and VL during isotonic exercise from D2 to D8 in Subject 8. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 17: The rSO₂ levels control leg VM and VL during isotonic exercise from D2 to D8 in Subject 9. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 18: The rSO₂ levels treatment leg VM and VL during isotonic exercise from D2 to D8 in Subject 9. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 19: The rSO₂ levels control leg VM and VL during isotonic exercise from D2 to D8 in Subject 10. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 20: The rSO₂ levels treatment leg VM and VL during isotonic exercise from D2 to D8 in Subject 10. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 21: The rSO₂ levels control leg VM and VL during isotonic exercise from D2 to D8 in Subject 11. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 22: The rSO₂ levels treatment leg VM and VL during isotonic exercise from D2 to D8 in Subject 11. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 23: The rSO₂ levels control leg VM and VL during isotonic exercise from D2 to D8 in Subject 12. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 24: The rSO₂ levels treatment leg VM and VL during isotonic exercise from D2 to D8 in Subject 12. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 25: The rSO₂ levels control leg VM and VL during isotonic exercise from D2 to D8 in Subject 13. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 26: The rSO₂ levels treatment leg VM and VL during isotonic exercise from D2 to D8 in Subject 13. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 27: The rSO₂ levels control leg VM and VL during isotonic exercise from D2 to D8 in Subject 14. (a) D2 (b) D3 (c) D4 (d) D5 (e) D6 (f) D7 (g) D8. The time displayed in the graph is the respective end of that trial




Figure F- 28: The rSO₂ levels treatment leg VM and VL during isotonic exercise from D3 to D8 in Subject 14. (a) D3 (b) D4 (c) D5 (d) D6 (e) D7 (f) D8. The time displayed in the graph is the respective end of that trial